WO2008151510A1 - Preparation of 4-(fluorophenyl)-6-isopropyl-2-(n-methyl-n-methylsulfonylamino)- 5-formyl-pyrimidine - Google Patents
Preparation of 4-(fluorophenyl)-6-isopropyl-2-(n-methyl-n-methylsulfonylamino)- 5-formyl-pyrimidine Download PDFInfo
- Publication number
- WO2008151510A1 WO2008151510A1 PCT/CN2008/001083 CN2008001083W WO2008151510A1 WO 2008151510 A1 WO2008151510 A1 WO 2008151510A1 CN 2008001083 W CN2008001083 W CN 2008001083W WO 2008151510 A1 WO2008151510 A1 WO 2008151510A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chloride
- compound
- formula
- acid
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
Definitions
- the invention relates to a method for preparing a pharmaceutical compound, in particular to an intermediate of the hypolipidemic drug rosuvastatin calcium, 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonyl).
- Rosuvastatin calcium is a clinically used hypolipidemic drug with the chemical name (+) - (3R, 5S) -7-[4-(4-fluorophenyl)-6-isopropyl-2 - (N-Methyl-N-methylsulfonylamino)pyrimidin-5-yl]-3,5-dihydroxy-6(E)-heptenoic acid calcium (2:1), the chemical structural formula is as follows -
- U.S. Patent No. 5,260,440 discloses rosuvastatin and methods for its synthesis.
- the method comprises the following steps: (1), (3 R) -3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphine methylene hexanoate and 4 (4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde (referred to as substituted pyrimidine-5-formaldehyde) condensation; (2), off The protecting group on the 3-hydroxy group is a hydroxy keto ester; (3) reducing the 5-carbonyl group to give a chiral 3,5-dihydroxyheptenoate; (4) hydrolyzing 3, 5-dihydroxyglycidyl The acid ester is converted to a calcium salt.
- the preparation is as follows:
- reaction raw material DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
- DDQ 4-methylmorphine-N-oxide
- TPAP peric acid tetra Propyl ammonium
- diisobutyl aluminum hydride are expensive;
- the technical problem to be solved by the present invention is to overcome the above-mentioned deficiencies, and to provide a preparation of 4-(4-fluorophenyl)-6-isopropyl- 2_(N-A) which is low in cost, simple in reaction, and suitable for industrial production.
- the present invention provides a method of rosuvastatin intermediate 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde.
- the method of the present invention specifically includes the following steps:
- Another object of the present invention is to provide a dihydropyrimidinone compound of the formula 2 having a melting point of from 174 ° C to 178 ° C.
- This compound is obtained by reacting isobutyrylacetonitrile with 4-fluorobenzaldehyde and urea in the presence of a protic compound and a metal salt.
- a further object of the present invention is to provide a hydroxypyrimidine compound of the formula 3 having a melting point of 199. rc (decomposed). This compound is obtained by oxidizing a dihydropyrimidinone compound of the formula 2.
- Still another object of the present invention is to provide a 2-(N-methyl-N-methylsulfonylamino)pyrimidine compound of the formula 4 which has a melting point of from 208 °C to 212 °C.
- This compound is obtained by reacting a hydroxypyrimidine compound of the formula 3 with an organic sulfonyl halide or an organic sulfonic acid anhydride, and reacting the resulting reaction product with N-methylmethanesulfonamide.
- step 1 :
- Isobutyrylacetonitrile is reacted with 4-fluorobenzaldehyde in the presence of a protic compound and a metal salt.
- the protic compound may be an inorganic acid or a salt thereof, such as sulfuric acid, hydrochloric acid, boric acid, phosphoric acid, nitric acid or sodium hydrogen sulfate; an organic sulfonic acid such as methanesulfonic acid, benzenesulfonic acid or substituted benzenesulfonic acid; and the like; Acetic acid, propionic acid or benzoic acid; etc.; alcohol, such as methanol, ethanol or butanol.
- protic acids such as sulfuric acid, hydrochloric acid, boric acid, methanesulfonic acid and acetic acid. More preferred is sulfuric acid.
- Protic compounds can be used singly or in combination.
- the proton compound is preferably used in an amount of from 0.01 to 1 mole, more preferably from 0.1 to 1 mole, per mole of the isobutyryl acetonitrile.
- the metal salt used in the reaction may be cuprous chloride (I:), copper chloride (11), copper acetate (11), ferrous chloride ( ⁇ ), ferric chloride (m), aluminum chloride, Nickel bromide ( ⁇ ), tin chloride ( ⁇ ), titanium tetrachloride or magnesium bromide.
- cuprous chloride (I) copper chloride (11), iron (III) chloride and nickel bromide (11).
- cuprous chloride (I) and the metal salt may contain water of crystallization, which may be used singly or in combination.
- the urea may be preferably used in an amount of from 0.5 to 10 moles, more preferably from 1.5 to 3 moles, per mole of the isobutyrylacetonitrile.
- the reaction can be carried out in the presence or absence of a solvent, and solvents which can be used include alcohols such as methyl alcohol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, sec-butanol and tert-butanol; Ethers such as diethyl ether, isopropyl ether, tetrahydrofuran and dimethoxyethane; nitriles such as acetonitrile, propionitrile, butyronitrile and isobutyronitrile; halogenated aliphatic hydrocarbons such as dichloromethane, dichloroethane , chloroform and carbon tetrachloride; aromatics such as benzene, toluene and xylene; halogenated aromatic hydrocarbons such as chlorobenzene; and nitrated aromatic hydrocarbons such as nitrobenzene.
- solvents which can be used include alcohol
- methanol, ethanol or isopropanol is especially preferred.
- the solvent can be used singly or in combination.
- the amount of the solvent used may be preferably from 0.1 to 10 liters, more preferably from 0.3 to 2 liters per mole of the isobutyryl acetonitrile. The amount can vary depending on the uniformity and dispersibility of the reaction mixture.
- the reaction can be carried out by reacting isobutyrylacetonitrile, 4-fluorobenzaldehyde and urea in a solvent in the presence of a protic compound and a metal salt in an inert gas atmosphere.
- the reaction can be preferably carried out at a temperature of from -10 Torr to 200 ° C, more preferably from 30 ° C to 100 ° C. There are no specific restrictions on environmental stress.
- the product formed by the reaction i.e., the dihydropyrimidinone compound of the formula 2, can be isolated and purified according to a conventional method such as distillation, crystallization, recrystallization, and column chromatography.
- the dihydropyrimidinone compound of the formula 2 i.e., the reaction product of the step (1), is oxidized to give a hydroxypyrimidine compound of the formula 3.
- the oxidation (or dehydrogenation) can be carried out by various conventional methods, and it is preferred to use an oxidation process of nitric acid because the oxidation process is easy to proceed and the post-treatment of the reaction product is easy.
- the nitric acid may be preferably used in an amount of 1 to 20 moles, more preferably .3 to 15 moles per 1 mole of the dihydropyrimidinone compound of the formula 2.
- a concentration of from 40 to 80%, more preferably from 50 to 70%, of nitric acid can be used.
- the oxidation can be carried out in the presence or absence of a solvent, and there is no particular limitation with respect to the solvent to be used.
- the solvent includes a carboxylic acid such as acetic acid, propionic acid and butyric acid.
- the solvent can be used singly or in combination.
- the amount of the solvent is preferably used in an amount of from 0.1 to 7 liters, more preferably from 0.5 to 3 liters per gram of the dihydrodipyridone compound.
- the amount can vary depending on the uniformity and dispersibility of the reaction mixture.
- Oxidation can be carried out by allowing the dihydropyrimidinone compound and nitric acid to be carried out in a solvent or not in an inert gas atmosphere.
- the oxidation may preferably be carried out at a temperature of -10 ° C to 10 (TC, more preferably - 5 ° C - 5 (TC).
- TC -10 ° C to 10
- a reaction initiator such as sodium nitrite may be added to the reaction system. Accelerate the oxidation rate.
- the product formed by the reaction i.e., the hydroxypyrimidine compound of the formula 3, can be isolated and purified according to a conventional method such as distillation, crystallization, recrystallization, and column chromatography.
- the hydroxypyrimidine compound that is, the reaction product of the step (2) is reacted with an organic sulfonyl halide having the formula 5:
- R' is a hydrocarbon group and X is a halogen atom
- reaction product of the step (2) is reacted with an organic sulfonyl halide having the formula 5
- the resulting product is further reacted with N-methyl-N-methanesulfonamide.
- R' is a hydrocarbon group which may have one or more substituents.
- the hydrocarbon group include an alkyl group such as a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a decyl group, a heptyl group, an octyl group, a decyl group and a fluorenyl group, and more specifically a group having 1 to 6 carbon atoms.
- An alkyl group especially a fluorenyl group having 1 to 4 carbon atoms; a fluoroalkyl group such as a trifluoromethyl group, a nonafluorobutyl group, a decafluorohexyl group, a heptadecafluorooctyl group, and a hexafluoroaryl group; a cycloalkyl group such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group and a cyclohexyl group; and an aryl group such as a benzyl group, a phenylethyl group and a phenylpropyl group; and an aryl group including an unsubstituted and substituted phenyl group Or naphthyl, such as phenyl, naphthyl, tolyl, dimethyl Phenyl, trimethylphenyl, triisopropy
- a hydrocarbyl group may carry one or more substituents provided that the substituent does not interfere with the reaction involved, and the hydrocarbyl group may be in any isomeric configuration, such as n-, iso-, and t-.
- substituents when R' is aryl include, for example, phenyl or naphthyl (especially phenyl) which is unsubstituted or carries 1, 2 or 3 substituents.
- the substituents may be independently selected, for example, a fluorenyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a halogen, and a nitro group.
- X is a halogen atom such as fluorine, chlorine, bromine and iodine.
- sulfonyl halide examples include methanesulfonyl chloride, ethanesulfonyl chloride, 1-propylsulfonyl chloride, 2-propanesulfonyl chloride, trifluoromethylsulfonyl fluoride, trifluoromethylsulfonyl chloride, nonafluorobutylsulfonyl fluoride, and ten.
- sulfonic acid anhydride examples include methanesulfonic anhydride, trifluoromethanesulfonic anhydride, benzenesulfonic anhydride, and p-toluenesulfonic anhydride. Preferred are trifluoromethanesulfonic anhydride, benzenesulfonic anhydride and p-toluenesulfonic anhydride.
- the sulfonyl halide or sulfonic acid anhydride may be preferably used in an amount of from 0.1 to 20 moles, more preferably from 0.5 to 5 moles, and most preferably from 1 to 2 moles per 1 mole of the hydroxy compound. .
- N-methylmethanesulfonamide may be preferably used in an amount of from 0.1 to 30 mol, more preferably from 1 to 5 mol, per 1 mol of the hydroxypyrimidine compound.
- the reaction of the step (3) is preferably carried out in the presence of a base.
- the base examples include alkali metal carbonates such as sodium carbonate and potassium carbonate; alkali metal hydrogencarbonates such as sodium hydrogencarbonate; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide; alkali metal alcohols Salts such as sodium methoxide, sodium t-butoxide, potassium t-butoxide and sodium t-pentoxide; and tertiary amines such as triethylamine, triisopropylamine, diisopropylethylamine and pyridine. Preference is given to sodium carbonate, potassium carbonate, potassium t-butoxide, potassium t-amylate, triethylamine and pyridine. Potassium carbonate, sodium t-butoxide and triethylamine are especially preferred. Most preferred are potassium carbonate and sodium t-butoxide.
- the bases can be used singly or in combination.
- the base may preferably be 0.1 to 30 moles, more preferably 1 to 5 moles per 1 mole of the hydroxypyrimidine compound. The amount is used. The entire amount of the base may be added to the reaction system before the start of the reaction or the base may be added to the reaction system in portions after the start of the reaction.
- the reaction can be carried out in the presence or absence of a solvent, and there is no particular limitation with respect to the solvent to be used, as long as the solvent does not disturb the reaction.
- the solvent include water; ketones such as acetone, methyl ethyl ketone and diethyl ketone; ethers such as diethyl ether and tetrahydrofuran; esters such as ethyl acetate, ethyl propionate, and butyl acetate; nitriles such as acetonitrile and propionitrile; For example, N, N-dimethylformamide and N-methylpyrrolidone; sulfoxides such as dimethyl sulfoxide; ureas such as N,N-dimethylimidazolidinone.
- acetone tetrahydrofuran
- ethyl acetate butyl acetate
- acetonitrile N,N-dimethylformamide and dimethyl sulfoxide.
- ethyl acetate butyl acetate and acetonitrile.
- butyl acetate and acetonitrile are preferred.
- the solvent can be used singly or in combination.
- the solvent is preferably used in an amount of from 0.01 to 100 liters, more preferably from 0.5 to 5 liters per 1 mole of the hydroxypyrimidine compound.
- the amount can vary depending on the uniformity and dispersibility of the reaction mixture.
- the reaction can be carried out by reacting a hydroxypyrimidine compound and an organic sulfonyl halide or a sulfonic acid anhydride in a solvent in an inert gas atmosphere under stirring in the presence of a base.
- the reaction can be preferably carried out at a temperature of from - 30 ° C to 250 ° C, more preferably from 0 ° C to 15 ° C.
- the product formed by the reaction i.e., the 2-(N-methyl-N-methylsulfonylamino)pyrimidine compound of the formula (4), can be isolated and purified according to a conventional method such as distillation, crystallization, recrystallization, and column chromatography.
- step (3) the hydroxypyrimidine compound of the formula 3 and a halogenating agent such as a chlorinating agent, an organic sulfonyl halide of the formula 5:
- R' is the same as defined above, X is a halogen atom, or a compound of formula (3) is reacted with an organic sulfonic anhydride of formula 5a:
- R' has the same definition as above.
- halogenating agent examples include phosphorus oxychloride and sulfuryl chloride.
- the halogenating agents can be used singly or in combination.
- the halogenating agent may preferably be used in an amount of from 0.1 to 50 moles, more preferably from 1 to 20 moles, and most preferably from 1. 5 to 10 moles per 1 mole of the hydroxypyrimidine compound.
- organic sulfonyl halide and the sulfonic acid anhydride examples are those described above.
- the organosulfonyl halide and the sulfonic acid anhydride are preferably used in an amount of from 0.1 to 20 moles, more preferably from 0.5 to 5 moles, and most preferably from 1 to 2 moles per 1 mole of the hydroxypyrimidine compound.
- the reaction can be carried out in the presence or absence of a solvent
- the solvent to be used is not particularly limited, and examples of the solvent include aromatic hydrocarbons such as toluene; halogenated aromatic hydrocarbons such as chlorobenzene; nitrated hydrocarbons such as nitrobenzene; Aliphatic hydrocarbons such as dichloromethane and 1,2-dichloroacetamidine; amides such as N,N-dimethylformamide; water (not suitable for chlorinating agents); nitriles such as acetonitrile and propionitrile; Carboxylic esters such as ethyl acetate, ethyl propionate and butyl acetate; ketones such as acetone, methyl ethyl ketone and diethyl ketone; and ethers such as diethyl ether and tetrahydrofuran.
- aromatic hydrocarbons such as toluene
- halogenated aromatic hydrocarbons such as chloro
- the solvent may be preferably used in an amount of from 0.01 to 10 liters per 1 mole of the hydroxypyrimidine compound, more preferably in an amount of from 0.1 to 1 liter, for the reaction using a halogenating agent.
- the amount can vary depending on the homogeneity and dispersibility of the reaction mixture.
- the solvent may be preferably used in an amount of from 0.1 to 50 liters, more preferably from 0.5 to 2 liters per mole of the hydroxypyrimidine compound, using a sulfonyl chloride or a sulfonic acid anhydride.
- the amount may vary depending on the uniformity of the reaction mixture.
- the reaction can be carried out by reacting a hydroxypyrimidine compound and a halogenating agent in a solvent with or without stirring in an inert gas atmosphere.
- the reaction can be preferably carried out at a temperature of from 0 ° C to 200 ° C, more preferably from 50 ° C to 150 ° C. There are no specific restrictions on environmental stress.
- the reaction can be carried out by reacting a hydroxypyrimidine compound and a sulfonyl halide or a sulfonic acid anhydride in a solvent with or without stirring in an inert gas atmosphere.
- the reaction can be preferably carried out at a temperature of from - 30 ° C to 20 (TC, more preferably from 0 to 80 Torr.
- TC - 30 ° C to 20
- the product formed by the reaction i.e., a 2-substituted pyrimidine compound such as a chloropyrimidine compound or a sulfonyloxypyrimidine compound
- a 2-substituted pyrimidine compound such as a chloropyrimidine compound or a sulfonyloxypyrimidine compound
- a conventional method such as distillation, crystallization, recrystallization, and column chromatography.
- the 2-substituted pyrimidine compound prepared in the step (3) such as a chloropyrimidine compound or a sulfonyloxypyrimidine compound, is reacted with an amine compound having the formula 6:
- ⁇ and ⁇ have the same definitions as above.
- Examples of ⁇ and R 2 include a hydrogen atom, a fluorenyl group such as a methyl group, an ethyl group, a propyl group, a butyl group, and a pentyl group. And a fluorenyl group; a mercaptosulfonyl group such as a methylsulfonyl group; and an arylsulfonyl group such as a benzenesulfonyl group and a p-toluenesulfonyl group.
- the amine compound may preferably be used in an amount of from 0.1 to 30 moles, more preferably from 1 to 5 moles per 1 mole of the 2-substituted pyrimidine compound.
- the reaction is preferably carried out in the presence of a base, and examples of the base are those described above.
- the base may be preferably used in an amount of from 0.1 to 30 moles, more preferably from 1 to 5 moles per 1 mole of the 2-substituted hydroxypyrimidine compound.
- the reaction can be carried out in the presence or absence of a solvent
- the solvent to be used is not particularly limited, and examples of the solvent include water; ketones such as acetone, methyl ethyl ketone and diethyl ketone; ethers such as diethyl ether and tetrahydrofuran; Ethyl acetate, ethyl propionate and butyl acetate; nitriles such as acetonitrile and propionitrile; amides such as N, N-dimethylformamide and N-methylpyrrolidone; sulfoxides such as dimethyl sulfoxide Sulfone; urea, such as N, N'-dimethylimidazolidinone.
- acetone Preference is given to acetone, tetrahydrofuran, ethyl acetate, butyl acetate, acetonitrile, N,N-dimethylformamide and dimethyl sulfoxide. Particularly preferred are ethyl acetate, butyl acetate and acetonitrile. Most preferred are butyl acetate and acetonitrile.
- the solvent can be used singly or in combination.
- the solvent is preferably used in an amount of from 0.01 to 100 liters, more preferably from 0.5 to 5 liters per mole of the 2-substituted pyrimidine compound.
- the amount can vary depending on the uniformity and dispersibility of the reaction mixture.
- the reaction can be carried out by allowing the 2-substituted pyrimidine compound and the amine compound to be carried out in a solvent in the presence of a base with or without stirring in an inert gas atmosphere.
- the reaction can be preferably carried out at a temperature of from -20 ° C to 25 (TC, more preferably from 25 ° C to 150 ° C.
- TC -20 ° C to 25
- step (3) the reaction is carried out in the presence or absence of a phase transfer catalyst, and the reaction in the presence of a phase transfer catalyst can be carried out in two branched liquid phases.
- the phase transfer catalyst include tetramethylammonium chloride, tetramethylammonium bromide, tetramethylammonium fluoride, tetraethylammonium chloride, tetraethylammonium bromide, tetrapropylammonium bromide, tetrapropylamine.
- tetrabutylammonium chloride Preferred are tetrabutylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium iodide, benzyltriethylammonium chloride, and hexadecanyltriethylphosphonium hinge. Most preferred are tetrabutylammonium bromide, benzyltriethylammonium chloride, and hexadecanyltrimethylammonium chloride.
- Each mole of 2-substituted pyrimidine compound, phase transfer catalyst may be 0. 01- 0. 5 moles, preferably 0. 05-0. The amount of 2 moles used.
- the product formed by the reaction that is, 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine of the formula 4 can be obtained according to a conventional method, for example Separation and purification are carried out by distillation, crystallization, recrystallization and column chromatography.
- step (4) 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine of the formula 4, ie, the step The reaction product of (3) is reacted with a reducing agent to obtain 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde having the formula 1. .
- the reducing agent may be diisobutylaluminum hydride, red aluminum, lithium tetrahydrogenate or the like. If diisobutylaluminum hydride is used, 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine (Formula 4) The 5% ⁇ 65% diisobutylaluminum hydride toluene solution was added dropwise in an organic solvent under an inert gas atmosphere, and the reaction was continued for several hours after the completion of the dropwise addition. After the completion of the reaction, the substituted pyrimidine-5-formaldehyde was obtained by separation and purification. The reaction temperature is - 20 ° C to 150 ° C, preferably - 10 ° C to 50 ° C.
- the organic solvent may be benzene, toluene, xylene, dichloromethane, chloroform, tetrahydrofuran, dioxane or other solvent which does not react with a reducing agent and a reaction raw material.
- the molar ratio of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine to diisobutylaluminum hydride is 1.0 0: 0-10. 0, Preferably 1. 0: 0. 8-4. 0.
- the method of the invention does not need to use highly toxic, expensive raw materials, has low process cost, simple reaction, high product yield, and is suitable for industrial production.
- Example 2 In the same manner as in Example 1, except that the amount of methanol was changed from 600 ml to 200 ml to obtain 103.5 g of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-3, 4-2 (1H)-
- the dihydropyrimidinone has the solid product of the characteristics of Example 1. The yield was 85% (based on the amount of isobutyrylacetonitrile).
- Example 2 In the same manner as in Example 1, except that the amount of urea was changed from 49.4 g (0.82 raol) to 56.63 g (0.94 mol) to obtain 106.3 g of 4-(4-fluorophenyl)-6-isopropyl-5-cyano group. - 3, 4-2 (1H)-Dihydropyrimidinone has the solid product of the characteristics of Example 1. The yield was 87.2% (based on the amount of isobutyrylacetonitrile).
- the reaction mixture was poured into 162 ml of water, and the aqueous mixture was neutralized by adding 78. lg of an aqueous sodium hydroxide solution (45 wt%), and the aqueous mixture was crystallized by precipitation.
- the crystalline product was collected by filtration and dried to give 28.3 g of 4-(4- fluorophenyl) - 2 - s yl -6 - isopropyl - 5-cyanopyrimidine as white crystals.
- the yield was 93% (based on the amount of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-3,4-2(1H)-dihydropyrimidinone).
- the mixture was reacted at a temperature of from 10 ° C to 15 ° C for 2 hours. After the completion of the reaction, 500 ml of water was poured into the reaction mixture, and the aqueous mixture was precipitated by adding 137 g of an aqueous aqueous sodium hydroxide solution (45 wt%) to precipitate crystals. The crystalline product was collected by filtration and dried to give 40. 6 g of 4-(4-fluorophenyl)-2-hydroxy-6-isopropyl-5-cyanopyrimidine as a colorless crystal. The yield was 92% (based on the amount of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-3,4-2(1H)-dihydropyrimidinone).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
4- (4-氟苯基) -6-异丙基 -2- (N-甲基 -N-甲磺酰氨基) 嘧啶 -5-甲醛的制备方法 技术领域 Process for the preparation of 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde
本发明涉及药物化合物制备方法,具体涉及降血脂药瑞舒伐他汀钙的中间体 4一 (4一氟苯基) 一 6—异丙基一 2— (N—甲基一 N—甲磺酰氨基)嘧啶一 5—甲 醛的制备方法。 背景技术 The invention relates to a method for preparing a pharmaceutical compound, in particular to an intermediate of the hypolipidemic drug rosuvastatin calcium, 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonyl). A method for preparing aminopyrimidine-5-formaldehyde. Background technique
瑞舒伐他汀钙 (rosuvastatin calcium) 是临床应用的降血脂药物, 化学名称 为 (+) - (3R, 5S) -7-[4- (4-氟苯基) -6-异丙基 -2- (N-甲基 -N-甲磺酰基氨基) 嘧啶 -5-基] -3, 5-二羟基 -6 (E) -庚烯酸钙 (2: 1 ), 化学结构式如下- Rosuvastatin calcium is a clinically used hypolipidemic drug with the chemical name (+) - (3R, 5S) -7-[4-(4-fluorophenyl)-6-isopropyl-2 - (N-Methyl-N-methylsulfonylamino)pyrimidin-5-yl]-3,5-dihydroxy-6(E)-heptenoic acid calcium (2:1), the chemical structural formula is as follows -
美国专利 US5260440公开了瑞舒伐他汀及其合成方法。 该方法包括如下步 骤: (1 )、 (3 R) -3- (叔丁基二甲基硅氧基) -5-氧代 -6-三苯基膦亚甲基己酸甲酯 与 4一 (4一氟苯基) 一 6—异丙基一 2— (N—甲基一N—甲磺酰氨基) 嘧啶一 5 一甲醛(简称取代嘧啶 -5-甲醛)缩合; (2)、 脱去 3-羟基上的保护基得羟基酮酸 酯; (3 )、 还原 5-羰基得到手性的 3 , 5-二羟基庚烯酸酯; (4)、 水解 3, 5-二羟 基庚稀酸酯并转化为钙盐。 U.S. Patent No. 5,260,440 discloses rosuvastatin and methods for its synthesis. The method comprises the following steps: (1), (3 R) -3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphine methylene hexanoate and 4 (4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde (referred to as substituted pyrimidine-5-formaldehyde) condensation; (2), off The protecting group on the 3-hydroxy group is a hydroxy keto ester; (3) reducing the 5-carbonyl group to give a chiral 3,5-dihydroxyheptenoate; (4) hydrolyzing 3, 5-dihydroxyglycidyl The acid ester is converted to a calcium salt.
上述方法的中间体 4一 (4—氟苯基) 一 6—异丙基一 2_ (N—甲基一 N—甲 磺酰氨基)嘧啶一 5—甲醛的制备比较困难, 反应步骤长, 收率低, 原料毒性大。 Intermediate 4 -(4-fluorophenyl)-6-isopropyl- 2_(N-methyl-N-A) The preparation of sulfonylaminopyrimidine-5-formaldehyde is difficult, the reaction step is long, the yield is low, and the raw material is highly toxic.
该制备如下式所示: The preparation is as follows:
由上式可知该方法存在下列缺陷: It can be seen from the above formula that the method has the following drawbacks:
( 1 ) 合成路线长, 需要 8步反应; (1) The synthetic route is long and requires 8 steps of reaction;
(2) 反应原料 DDQ (2,3-二氯-5,6-二氰基-1,4苯醌) 毒性大, 原料 4-甲基 吗林 -N-氧化物和 TPAP (过钌酸四丙基铵)及二异丁氢化铝等价格昂贵; (2) The reaction raw material DDQ (2,3-dichloro-5,6-dicyano-1,4-benzoquinone) is highly toxic, and the raw materials are 4-methylmorphine-N-oxide and TPAP (peric acid tetra Propyl ammonium) and diisobutyl aluminum hydride are expensive;
(3 )还原反应需要 - 74°C的低温,能耗高且设备投资大,不利于工业化生产; (3) Reducing reaction requires - 74 ° C low temperature, high energy consumption and large equipment investment, which is not conducive to industrial production;
(4) 反应总收率低。 发明内容 (4) The total reaction yield is low. Summary of the invention
本发明要解决的技术问题在于克服上述不足之处, 提供一种成本低、 反应 简单、 宜于工业化生产的制备 4一 (4—氟苯基) —6—异丙基一 2_ (N_甲基一 N—甲磺酰氨基) 嘧啶一 5—甲醛的方法。 The technical problem to be solved by the present invention is to overcome the above-mentioned deficiencies, and to provide a preparation of 4-(4-fluorophenyl)-6-isopropyl- 2_(N-A) which is low in cost, simple in reaction, and suitable for industrial production. A method of thio-N-methylsulfonylamino)pyrimidine-5-formaldehyde.
本发明提供了一种瑞舒伐他汀中间体 4一(4-氟苯基)一6—异丙基一 2_ (N 一甲基—N—甲磺酰氨基) 嘧啶一 5—甲醛的方法。 The present invention provides a method of rosuvastatin intermediate 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde.
4- (4-氟苯基) 一6—异丙基一 2— (N—甲基一 N—甲磺酰氨基) 嘧啶一 5 一甲醛的结构式为: 4-(4-fluorophenyl)-6-isopropyl-2-(-N-methyl-N-methylsulfonylamino)pyrimidine-5 The structural formula of a formaldehyde is:
本发明的方法如下列反应式所示: The method of the present invention is as shown in the following reaction formula:
本发明的方法具体包括如下步骤: The method of the present invention specifically includes the following steps:
( 1 )、异丁酰乙腈与 4-氟苯甲醛和脲在质子化合物和金属盐存在下反应,生 成式 2的二氢嘧啶酮化合物; (1), isobutyrylacetonitrile and 4-fluorobenzaldehyde and urea are reacted in the presence of a protic compound and a metal salt to form a dihydropyrimidinone compound of formula 2;
(2)、 氧化式 2的二氢嘧啶酮化合物, 生成具有式 3的羟基嘧啶化合物; (2) oxidizing a dihydropyrimidinone compound of formula 2 to form a hydroxypyrimidine compound having formula 3;
(3 )、式 3的羟基嘧啶化合物与有机磺酰卤或有机磺酸酐反应, 再使生成的 反应产物与 N-甲基甲磺酰胺反应, 生成式 4 的 2- (N-甲基 -N-甲磺酰基氨基)嘧 啶化合物; (4)、 式 4 的 2- (N-甲基 -N-甲磺酰氨基) 嘧啶化合物与还原剂反应, 生成 具有式 1的 4— (4-氟苯基) 一6—异丙基一 2— (N—甲基一N—甲磺酰氨基)嘧 啶一 5—甲醛。 (3) The hydroxypyrimidine compound of the formula 3 is reacted with an organic sulfonyl halide or an organic sulfonic acid anhydride, and the resulting reaction product is reacted with N-methylmethanesulfonamide to form 2-(N-methyl-N of the formula 4). -methanesulfonylamino)pyrimidine compound; (4) The 2-(N-methyl-N-methylsulfonylamino)pyrimidine compound of the formula 4 is reacted with a reducing agent to form 4-(4-fluorophenyl)-6-isopropyl-I having the formula 1. 2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde.
本发明的另一目的是提供了一种式 2的二氢嘧啶酮化合物, 其熔点为 174°C -178°C。该化合物是通过异丁酰乙腈与 4-氟苯甲醛和脲在质子化合物和金属盐存 在下反应制得的。 Another object of the present invention is to provide a dihydropyrimidinone compound of the formula 2 having a melting point of from 174 ° C to 178 ° C. This compound is obtained by reacting isobutyrylacetonitrile with 4-fluorobenzaldehyde and urea in the presence of a protic compound and a metal salt.
本发明的又一目的是提供了一种式 3的羟基嘧啶化合物, 其熔点为 199. rc (分解)。 该化合物是通过氧化式 2的二氢嘧啶酮化合物制得的。 A further object of the present invention is to provide a hydroxypyrimidine compound of the formula 3 having a melting point of 199. rc (decomposed). This compound is obtained by oxidizing a dihydropyrimidinone compound of the formula 2.
本发明还有一个目的是提供了一种式 4 的 2- (N-甲基 -N-甲磺酰基氨基)嘧 啶化合物, 其熔点为 208°C-212°C。 该化合物是通过式 3的羟基嘧啶化合物与有 机磺酰卤或有机磺酸酐反应, 再将生成的反应产物与 N-甲基甲磺酰胺反应制得 的。 Still another object of the present invention is to provide a 2-(N-methyl-N-methylsulfonylamino)pyrimidine compound of the formula 4 which has a melting point of from 208 °C to 212 °C. This compound is obtained by reacting a hydroxypyrimidine compound of the formula 3 with an organic sulfonyl halide or an organic sulfonic acid anhydride, and reacting the resulting reaction product with N-methylmethanesulfonamide.
根据本发明合成方法, 对其中的每个步骤进行如下详细描述。 Each of the steps is described in detail below in accordance with the synthesis method of the present invention.
步骤 (1 ): step 1 ):
异丁酰乙腈与 4-氟苯甲醛在质子化合物和金属盐存在下反应。 Isobutyrylacetonitrile is reacted with 4-fluorobenzaldehyde in the presence of a protic compound and a metal salt.
质子化合物可以是无机酸或其盐, 例如硫酸、 盐酸、 硼酸、 磷酸、 硝酸或 硫酸氢钠等; 有机磺酸, 例如甲磺酸、 苯磺酸或取代苯磺酸等; 有机羧酸, 例如 乙酸、 丙酸或苯甲酸等; 醇, 例如甲醇、 乙醇或丁醇等。 优选是质子酸, 例如硫 酸、 盐酸、 硼酸、 甲磺酸和乙酸。 更优选硫酸。 质子化合物可单独地或组合地使 用。 The protic compound may be an inorganic acid or a salt thereof, such as sulfuric acid, hydrochloric acid, boric acid, phosphoric acid, nitric acid or sodium hydrogen sulfate; an organic sulfonic acid such as methanesulfonic acid, benzenesulfonic acid or substituted benzenesulfonic acid; and the like; Acetic acid, propionic acid or benzoic acid; etc.; alcohol, such as methanol, ethanol or butanol. Preferred are protic acids such as sulfuric acid, hydrochloric acid, boric acid, methanesulfonic acid and acetic acid. More preferred is sulfuric acid. Protic compounds can be used singly or in combination.
每 1摩尔异丁酰乙腈, 质子化合物可优选以 0. 01-3摩尔, 更优选以 0. 1-1 摩尔的数量使用。 The proton compound is preferably used in an amount of from 0.01 to 1 mole, more preferably from 0.1 to 1 mole, per mole of the isobutyryl acetonitrile.
在反应中使用的金属盐可以是氯化亚铜( I:)、 氯化铜(11 )、 乙酸铜(11 )、 氯化亚铁(π )、 氯化铁 (m)、 氯化铝、 溴化镍 (ιι )、 氯化锡 (ιν )、 四氯化钛 或溴化镁。 优选是氯化亚铜 ( I )、 氯化铜 (11 )、 氯化铁(III)和溴化镍(11 )。 最优选是氯化亚铜( I ), 金属盐可含有结晶水, 金属盐可单独地或组合地使用。 The metal salt used in the reaction may be cuprous chloride (I:), copper chloride (11), copper acetate (11), ferrous chloride (π), ferric chloride (m), aluminum chloride, Nickel bromide (ιι), tin chloride (ιν), titanium tetrachloride or magnesium bromide. Preferred are cuprous chloride (I), copper chloride (11), iron (III) chloride and nickel bromide (11). Most preferred is cuprous chloride (I), and the metal salt may contain water of crystallization, which may be used singly or in combination.
每 1摩尔异丁酰乙腈, 金属盐可优选以 0. 001- 5摩尔, 更优选以 0. 01-0. 1 摩尔的数量使用。 1摩尔的量使用。 The amount of the use of the amount of 0. 001 - 5 moles, more preferably 0. 01-0.
每 1摩尔异丁酰乙腈, 4-氟苯甲醛可优选以 0. 5-10摩尔,更优选以 0. 9-1. 5 摩尔的数量使用。 5-1摩尔。 0. 5-1 moles, more preferably 0. 9-1. The amount of Moore is used.
每 1摩尔异丁酰乙腈, 脲可优选以 0. 5-10摩尔, 更优选以 1. 5-3摩尔的数 量使用。 The urea may be preferably used in an amount of from 0.5 to 10 moles, more preferably from 1.5 to 3 moles, per mole of the isobutyrylacetonitrile.
反应可以在溶剂存在下或不存在溶剂下进行, 可使用的溶剂包括醇,例如甲《 醇、 乙醇、 正丙醇、 异丙醇、 正丁醇、 异丁醇、 仲丁醇和叔丁醇; 醚, 例如乙醚、 异丙基醚、 四氢呋喃和二甲氧基乙烷; 腈, 例如乙腈、 丙腈、 丁腈和异丁腈; 卤 代脂族烃, 例如二氯甲垸、 二氯乙烷、 氯仿和四氯化碳; 芳香, 例如苯、 甲苯和 二甲苯; 卤代芳烃, 例如氯苯; 和硝化芳烃, 例如硝基苯。优选的是甲醇、 乙醇、 正丙醇、 异丙基醇、 正丁醇、 二异丙基醚、 四氢呋喃、 二甲氧基乙烷、 乙腈、 丁 腈、 异丁腈、 二氯甲烷、 二氯乙烷、 氯仿、 甲苯、 二甲苯和氯苯。 尤其优选的是 甲醇、 乙醇或异丙醇。 溶剂可单独或组合地使用。 The reaction can be carried out in the presence or absence of a solvent, and solvents which can be used include alcohols such as methyl alcohol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, sec-butanol and tert-butanol; Ethers such as diethyl ether, isopropyl ether, tetrahydrofuran and dimethoxyethane; nitriles such as acetonitrile, propionitrile, butyronitrile and isobutyronitrile; halogenated aliphatic hydrocarbons such as dichloromethane, dichloroethane , chloroform and carbon tetrachloride; aromatics such as benzene, toluene and xylene; halogenated aromatic hydrocarbons such as chlorobenzene; and nitrated aromatic hydrocarbons such as nitrobenzene. Preferred are methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol, diisopropyl ether, tetrahydrofuran, dimethoxyethane, acetonitrile, butyronitrile, isobutyronitrile, dichloromethane, dichloro Ethane, chloroform, toluene, xylene and chlorobenzene. Especially preferred is methanol, ethanol or isopropanol. The solvent can be used singly or in combination.
每 1摩尔异丁酰乙腈, 使用的溶剂量可优选以 0. 1- 10升, 更优选以 0. 3 - 2 升的数量使用。 数量可根据反应混合物的均匀性和分散性变化。 The amount of the solvent used may be preferably from 0.1 to 10 liters, more preferably from 0.3 to 2 liters per mole of the isobutyryl acetonitrile. The amount can vary depending on the uniformity and dispersibility of the reaction mixture.
反应可通过使异丁酰乙腈、 4-氟苯甲醛和脲在溶剂中在质子化合物和金属盐 存在下在惰性气体气氛中反应进行。 反应可优选在 - 10Ό- 200°C, 更优选 30°C -100'C的温度下进行。 关于环境压力没有特定限制。 The reaction can be carried out by reacting isobutyrylacetonitrile, 4-fluorobenzaldehyde and urea in a solvent in the presence of a protic compound and a metal salt in an inert gas atmosphere. The reaction can be preferably carried out at a temperature of from -10 Torr to 200 ° C, more preferably from 30 ° C to 100 ° C. There are no specific restrictions on environmental stress.
反应生成的产物, 即式 2的二氢嘧啶酮化合物可根据常规方法, 例如蒸馏、 结晶、 重结晶和柱色谱法分离和纯化。 The product formed by the reaction, i.e., the dihydropyrimidinone compound of the formula 2, can be isolated and purified according to a conventional method such as distillation, crystallization, recrystallization, and column chromatography.
步骤 (2) Step (2)
在步骤(2) 中, 式 2的二氢嘧啶酮化合物, 即步骤(1 ) 的反应产物被氧化 以得到式 3的羟基嘧啶化合物。 In the step (2), the dihydropyrimidinone compound of the formula 2, i.e., the reaction product of the step (1), is oxidized to give a hydroxypyrimidine compound of the formula 3.
氧化(或脱氢氧化)可以各种常规方法进行, 优选使用硝酸的氧化过程, 因 为该氧化过程容易进行, 反应产物的后处理容易。 The oxidation (or dehydrogenation) can be carried out by various conventional methods, and it is preferred to use an oxidation process of nitric acid because the oxidation process is easy to proceed and the post-treatment of the reaction product is easy.
每 1摩尔式 2的二氢嘧啶酮化合物, 硝酸可优选以 1-20摩尔, 更优选 .3-15 摩尔的数量使用。 优选可使用浓度为 40- 80%, 更优选 50-70%的硝酸。 The nitric acid may be preferably used in an amount of 1 to 20 moles, more preferably .3 to 15 moles per 1 mole of the dihydropyrimidinone compound of the formula 2. Preferably, a concentration of from 40 to 80%, more preferably from 50 to 70%, of nitric acid can be used.
氧化可以在溶剂存在下或不存在溶剂下进行,关于所使用的溶剂没有特定的 限制, 优选溶剂包括羧酸, 例如乙酸、 丙酸和丁酸。 溶剂可单独或组合地使用。 The oxidation can be carried out in the presence or absence of a solvent, and there is no particular limitation with respect to the solvent to be used. Preferably, the solvent includes a carboxylic acid such as acetic acid, propionic acid and butyric acid. The solvent can be used singly or in combination.
每 lg二氢嘧啶酮化合物,使用的溶剂量可优选以 0. 1-7升,更优选以 0. 5-3 升的数量使用。 数量可根据反应混合物的均匀性和分散性变化。 氧化可通过使二氢嘧啶酮化合物和硝酸在溶剂中在或不在惰性气体气氛中 进行。氧化可优选在 -10°C-10(TC, 更优选 - 5°C- 5(TC的温度下进行。 关于环境压 力没有特定限制。 反应引发剂, 例如亚硝酸钠, 可加入反应体系中以加速氧化速 率。 The amount of the solvent is preferably used in an amount of from 0.1 to 7 liters, more preferably from 0.5 to 3 liters per gram of the dihydrodipyridone compound. The amount can vary depending on the uniformity and dispersibility of the reaction mixture. Oxidation can be carried out by allowing the dihydropyrimidinone compound and nitric acid to be carried out in a solvent or not in an inert gas atmosphere. The oxidation may preferably be carried out at a temperature of -10 ° C to 10 (TC, more preferably - 5 ° C - 5 (TC). There is no particular limitation on the ambient pressure. A reaction initiator such as sodium nitrite may be added to the reaction system. Accelerate the oxidation rate.
反应生成的产物, 即式 3的羟基嘧啶化合物可根据常规方法, 例如蒸馏、 结 晶、 重结晶和柱色谱法分离和纯化。 The product formed by the reaction, i.e., the hydroxypyrimidine compound of the formula 3, can be isolated and purified according to a conventional method such as distillation, crystallization, recrystallization, and column chromatography.
步骤 (3) Step (3)
在步骤 (3) 中, 式 3 In step (3), Equation 3
的羟基嘧啶化合物, 即步骤 (2 ) 的反应产物与具有式 5的有机磺酰基卤反应: The hydroxypyrimidine compound, that is, the reaction product of the step (2) is reacted with an organic sulfonyl halide having the formula 5:
R, S02X R, S02X
式 5 Equation 5
其中 R' 是烃基, X是卤素原子, Wherein R' is a hydrocarbon group and X is a halogen atom,
或与具有式 5a的有机磺酸酐反应: Or react with an organic sulfonic anhydride having the formula 5a:
(R, S02 ) 20 (R, S02 ) 2 0
式 5a Equation 5a
其中 R' 与上述相同, Where R' is the same as above,
所述步骤 (2 ) 的反应产物与具有式 5的有机磺酰基卤反应后, 生成的产物 再与 N-甲基 -N-甲磺酰胺反应。 After the reaction product of the step (2) is reacted with an organic sulfonyl halide having the formula 5, the resulting product is further reacted with N-methyl-N-methanesulfonamide.
在式 5和 5a中, R' 是可带有一个或多个取代基的烃基。烃基的实例包括烷 基, 例如甲基、 乙基、 丙基、 丁基、 戊基、 巳基、 庚基、 辛基、 壬基和癸基, 更 具体地是含有 1-6个碳原子的烷基,尤其是含有 1-4个碳原子的垸基;氟代烷基, 例如三氟甲基、 九氟丁基、 十三氟己基、 十七氟辛基和二十一氟葵基; 环垸基, 例如环丙基、 环丁基、 环戊基和环己基; 和芳基, 例如苄基、 苯基乙基和苯基丙 基; 和芳基, 包括未取代和取代的苯基或萘基, 例如苯基、 萘基、 甲苯基、 二甲 苯基、 三甲苯基、 三异丙基苯基、 甲氧基苯基、 氯苯基和硝基苯基。 因此, 烃基 可以带有一个或多个取代基,其前提是取代基不扰乱所包含的反应,烃基可以采 用任何异构体构型, 例如正-、 异-、 和叔-。 在 R ' 是芳基时, 对其尤其合适的 含义包括例如未取代或带有 1、 2或 3个取代基的苯基或萘基(尤其是苯基)。取 代基可分别选自, 例如含有 1-4个碳原子的垸基、 含有 1-4个碳原子的烷氧基、 卤素和硝基。 In Formulae 5 and 5a, R' is a hydrocarbon group which may have one or more substituents. Examples of the hydrocarbon group include an alkyl group such as a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a decyl group, a heptyl group, an octyl group, a decyl group and a fluorenyl group, and more specifically a group having 1 to 6 carbon atoms. An alkyl group, especially a fluorenyl group having 1 to 4 carbon atoms; a fluoroalkyl group such as a trifluoromethyl group, a nonafluorobutyl group, a decafluorohexyl group, a heptadecafluorooctyl group, and a hexafluoroaryl group; a cycloalkyl group such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group and a cyclohexyl group; and an aryl group such as a benzyl group, a phenylethyl group and a phenylpropyl group; and an aryl group including an unsubstituted and substituted phenyl group Or naphthyl, such as phenyl, naphthyl, tolyl, dimethyl Phenyl, trimethylphenyl, triisopropylphenyl, methoxyphenyl, chlorophenyl and nitrophenyl. Thus, a hydrocarbyl group may carry one or more substituents provided that the substituent does not interfere with the reaction involved, and the hydrocarbyl group may be in any isomeric configuration, such as n-, iso-, and t-. Particularly suitable meanings when R' is aryl include, for example, phenyl or naphthyl (especially phenyl) which is unsubstituted or carries 1, 2 or 3 substituents. The substituents may be independently selected, for example, a fluorenyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms, a halogen, and a nitro group.
在式 5中, X是卤素原子, 例如氟、 氯、 溴和碘。 In Formula 5, X is a halogen atom such as fluorine, chlorine, bromine and iodine.
磺酰基卤的实例包括甲磺酰氯、 乙磺酰氯、 1-丙磺酰氯、 2-丙磺酰氯、 三氟 甲基磺酰氟、 三氟甲基磺酰氯、 九氟丁基磺酰氟、 十三氟已基磺酰氟、 十七氟辛 基磺酰氟、 二十一氟癸基磺酰氟、 苯磺酰氯、 1-萘磺酰氯、 2-萘磺酰氯、 对甲苯 磺酰氟、对甲苯磺酰氯、 2, 4, 6-三甲基苯磺酰氯、 2, 4, 6-三异丙基苯磺酰氯、 对甲氧基苯磺酰氯、 对氯苯磺酰氯和 2-硝基苯磺酰氯。 优选的是三氟甲基磺酰 氟、 苯磺酰氯、 1-萘磺酰氯、 2-萘磺酰氯、 对甲苯磺酰氯、 2, 4, 6-三甲基苯磺 酰氯、 2, 4, 6-三异丙基苯磺酰氯、 对甲氧基苯磺酰氯和对氯苯磺酰氯。 尤其优 选的是对甲苯磺酰氯、 2, 4, 6-三甲基苯磺酰氯、 2, 4, 6-三异丙基苯磺酰氯和 对甲氧基苯磺酰氯。 Examples of the sulfonyl halide include methanesulfonyl chloride, ethanesulfonyl chloride, 1-propylsulfonyl chloride, 2-propanesulfonyl chloride, trifluoromethylsulfonyl fluoride, trifluoromethylsulfonyl chloride, nonafluorobutylsulfonyl fluoride, and ten. Trifluorohexylsulfonyl fluoride, heptafluorooctylsulfonyl fluoride, diundosylfluorosulfonyl fluoride, benzenesulfonyl chloride, 1-naphthalenesulfonyl chloride, 2-naphthalenesulfonyl chloride, p-toluenesulfonyl fluoride, Tosyl chloride, 2,4,6-trimethylbenzenesulfonyl chloride, 2,4,6-triisopropylbenzenesulfonyl chloride, p-methoxybenzenesulfonyl chloride, p-chlorobenzenesulfonyl chloride and 2-nitrobenzene Sulfonyl chloride. Preferred are trifluoromethylsulfonyl fluoride, benzenesulfonyl chloride, 1-naphthalenesulfonyl chloride, 2-naphthalenesulfonyl chloride, p-toluenesulfonyl chloride, 2,4,6-trimethylbenzenesulfonyl chloride, 2, 4, 6 - Triisopropylbenzenesulfonyl chloride, p-methoxybenzenesulfonyl chloride and p-chlorobenzenesulfonyl chloride. Particularly preferred are p-toluenesulfonyl chloride, 2,4,6-trimethylbenzenesulfonyl chloride, 2,4,6-triisopropylbenzenesulfonyl chloride and p-methoxybenzenesulfonyl chloride.
磺酸酐的实例包括甲磺酸酐、 三氟甲基磺酸酐、 苯磺酸酐和对甲苯磺酸酐。 优选三氟甲基磺酸酐、 苯磺酸酐和对甲苯磺酸酐。 Examples of the sulfonic acid anhydride include methanesulfonic anhydride, trifluoromethanesulfonic anhydride, benzenesulfonic anhydride, and p-toluenesulfonic anhydride. Preferred are trifluoromethanesulfonic anhydride, benzenesulfonic anhydride and p-toluenesulfonic anhydride.
每 1 摩尔羟基化合物, 磺酰基卤或磺酸酐可优选以 0. 1-20摩尔, 更优选 0. 5- 5摩尔, 最优选 1-2摩尔的数量使用。 . The sulfonyl halide or sulfonic acid anhydride may be preferably used in an amount of from 0.1 to 20 moles, more preferably from 0.5 to 5 moles, and most preferably from 1 to 2 moles per 1 mole of the hydroxy compound. .
在随后的步骤中, 每 1 摩尔羟基嘧啶化合物, N-甲基甲磺酰胺可优选以 0. 1-30摩尔, 更优选 1-5摩尔的数量便用。 步骤(3 ) 的反应优选在碱存在下进 行。碱的实例包括碱金属碳酸盐, 例如碳酸钠和碳酸钾; 碱金属碳酸氢盐, 例如 碳酸氢钠;碱金属氢氧化物,例如氢氧化锂、氢氧化钠和氢氧化钾;碱金属醇盐, 例如甲醇钠、 叔丁醇钠、 叔丁醇钾和叔戊醇钠; 和叔胺, 例如三乙胺、 三异丙基 胺、 二异丙基乙胺和吡啶。 优选碳酸钠、 碳酸钾、 叔丁醇钾、 叔戊醇钾、 三乙胺 和吡啶。 尤其优选碳酸钾、 叔丁醇钠和三乙胺。 最优选碳酸钾和叔丁醇钠。碱可 单独地或组合地使用。 In the subsequent step, N-methylmethanesulfonamide may be preferably used in an amount of from 0.1 to 30 mol, more preferably from 1 to 5 mol, per 1 mol of the hydroxypyrimidine compound. The reaction of the step (3) is preferably carried out in the presence of a base. Examples of the base include alkali metal carbonates such as sodium carbonate and potassium carbonate; alkali metal hydrogencarbonates such as sodium hydrogencarbonate; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide; alkali metal alcohols Salts such as sodium methoxide, sodium t-butoxide, potassium t-butoxide and sodium t-pentoxide; and tertiary amines such as triethylamine, triisopropylamine, diisopropylethylamine and pyridine. Preference is given to sodium carbonate, potassium carbonate, potassium t-butoxide, potassium t-amylate, triethylamine and pyridine. Potassium carbonate, sodium t-butoxide and triethylamine are especially preferred. Most preferred are potassium carbonate and sodium t-butoxide. The bases can be used singly or in combination.
每 1摩尔羟基嘧啶化合物, 碱可优选以 0. 1-30摩尔, 更优选 1-5摩尔的数 量使用。全部数量的碱可在反应开始之前加入反应体系中或碱可在反应开始后分 批加入反应体系中。 The base may preferably be 0.1 to 30 moles, more preferably 1 to 5 moles per 1 mole of the hydroxypyrimidine compound. The amount is used. The entire amount of the base may be added to the reaction system before the start of the reaction or the base may be added to the reaction system in portions after the start of the reaction.
反应可以在溶剂存在下或不存在溶剂下进行,关于所使用的溶剂没有特定的 限制, 只要溶剂不扰乱反应即可。 溶剂的实例包括水; 酮, 例如丙酮、 甲乙酮和 二乙酮; 醚, 例如乙醚和四氢呋喃; 酯, 例如乙酸乙酯、 丙酸乙酯、和乙酸丁酯; 腈,例如乙腈和丙腈; 酰胺, 例如 N, N-二甲基甲酰胺和 N-甲基吡咯烷酮; 亚砜, 例如二甲基亚砜; 脲, 例如 N, N-二甲基咪唑啉酮。 优选丙酮、 四氢呋喃、 乙酸 乙酯、 乙酸丁酯、 乙腈、 N, N-二甲基甲酰胺和二甲基亚砜。 尤其优选乙酸乙酯、 乙酸丁酯和乙腈。 最优选乙酸丁酯和乙腈。 溶剂可单独或组合地使用。 The reaction can be carried out in the presence or absence of a solvent, and there is no particular limitation with respect to the solvent to be used, as long as the solvent does not disturb the reaction. Examples of the solvent include water; ketones such as acetone, methyl ethyl ketone and diethyl ketone; ethers such as diethyl ether and tetrahydrofuran; esters such as ethyl acetate, ethyl propionate, and butyl acetate; nitriles such as acetonitrile and propionitrile; For example, N, N-dimethylformamide and N-methylpyrrolidone; sulfoxides such as dimethyl sulfoxide; ureas such as N,N-dimethylimidazolidinone. Preferred are acetone, tetrahydrofuran, ethyl acetate, butyl acetate, acetonitrile, N,N-dimethylformamide and dimethyl sulfoxide. Particularly preferred are ethyl acetate, butyl acetate and acetonitrile. Most preferred are butyl acetate and acetonitrile. The solvent can be used singly or in combination.
每 1摩尔羟基嘧啶化合物, 溶剂可优选以 0. 01- 100升, 更优选以 0. 5- 5升 的数量使用。 数量可根据反应混合物的均匀性和分散性变化。 The solvent is preferably used in an amount of from 0.01 to 100 liters, more preferably from 0.5 to 5 liters per 1 mole of the hydroxypyrimidine compound. The amount can vary depending on the uniformity and dispersibility of the reaction mixture.
反应可通过使羟基嘧啶化合物和有机磺酰基卤或磺酸酐在溶剂中在碱的存 在下在搅拌下在惰性气体气氛中反应进行。 反应可优选在 - 30°C- 250°C, 更优选 0°C-15(TC的温度下进行。 关于环境压力没有特定限制。 The reaction can be carried out by reacting a hydroxypyrimidine compound and an organic sulfonyl halide or a sulfonic acid anhydride in a solvent in an inert gas atmosphere under stirring in the presence of a base. The reaction can be preferably carried out at a temperature of from - 30 ° C to 250 ° C, more preferably from 0 ° C to 15 ° C. There is no particular limitation on the environmental pressure.
反应生成的产物, 即式 (4) 的 2- (N-甲基 -N-甲磺酰基氨基) 嘧啶化合物 可根据常规方法, 例如蒸馏、 结晶、 重结晶和柱色谱法分离和纯化。 The product formed by the reaction, i.e., the 2-(N-methyl-N-methylsulfonylamino)pyrimidine compound of the formula (4), can be isolated and purified according to a conventional method such as distillation, crystallization, recrystallization, and column chromatography.
在步骤 (3 ) 中, 式 3的羟基嘧啶化合物与卤化剂, 例如氯化剂、 式 5的有 机磺酰基卤: In the step (3), the hydroxypyrimidine compound of the formula 3 and a halogenating agent such as a chlorinating agent, an organic sulfonyl halide of the formula 5:
R' S02X R' S02X
式 5 Equation 5
其中 R' 是具有上述相同的定义, X是卤素原子, 或式 (3 ) 化合物与式 5a 的有机磺酸酐反应: Wherein R' is the same as defined above, X is a halogen atom, or a compound of formula (3) is reacted with an organic sulfonic anhydride of formula 5a:
(R, S02 ) 20 (R, S02 ) 2 0
式 5a Equation 5a
其中 R' 具有上述相同的定义。 Where R' has the same definition as above.
卤化剂的实例包括磷酰氯和磺酰氯。 卤化剂可单独地或组合地使用。 Examples of the halogenating agent include phosphorus oxychloride and sulfuryl chloride. The halogenating agents can be used singly or in combination.
每 1摩尔羟基嘧啶化合物,卤化剂可优选以 0. 1-50摩尔,更优选 1-20摩尔, 最优选 1. 5-10摩尔的数量使用。 The halogenating agent may preferably be used in an amount of from 0.1 to 50 moles, more preferably from 1 to 20 moles, and most preferably from 1. 5 to 10 moles per 1 mole of the hydroxypyrimidine compound.
有机磺酰基卤和磺酸酐的实例是上述的那些物质。 每 1摩尔羟基嘧啶化合物, 有机磺酰基卤和磺酸酐可优选以 0. 1-20摩尔, 更优选 0. 5-5摩尔, 最优选 1-2摩尔的数量使用。 Examples of the organic sulfonyl halide and the sulfonic acid anhydride are those described above. The organosulfonyl halide and the sulfonic acid anhydride are preferably used in an amount of from 0.1 to 20 moles, more preferably from 0.5 to 5 moles, and most preferably from 1 to 2 moles per 1 mole of the hydroxypyrimidine compound.
反应可以在溶剂存在下或不存在溶剂下进行,关于所使用的溶剂没有特定的 限制, 溶剂的实例包括芳香烃, 例如甲苯; 卤代芳烃, 例如氯苯; 硝化烃, 例如 硝基苯; 卤代脂族烃, 例如二氯甲烷和 1 , 2-二氯乙垸; 酰胺, 例如 N, N-二甲 基甲酰胺; 水 (不适用于氯化剂); 腈, 例如乙腈和丙腈; 羧酸酯, 例如乙酸乙 酯、 丙酸乙酯和乙酸丁酯; 酮, 例如丙酮、 甲乙酮和二乙酮; 和醚, 例如乙醚和 四氢呋喃。 优选乙酸丁酯、 甲苯、 二氯甲垸、 乙腈、 氯苯、 硝基苯和^ N-二甲 基甲酰胺。 溶剂可单独或组合地使用。 The reaction can be carried out in the presence or absence of a solvent, and the solvent to be used is not particularly limited, and examples of the solvent include aromatic hydrocarbons such as toluene; halogenated aromatic hydrocarbons such as chlorobenzene; nitrated hydrocarbons such as nitrobenzene; Aliphatic hydrocarbons such as dichloromethane and 1,2-dichloroacetamidine; amides such as N,N-dimethylformamide; water (not suitable for chlorinating agents); nitriles such as acetonitrile and propionitrile; Carboxylic esters such as ethyl acetate, ethyl propionate and butyl acetate; ketones such as acetone, methyl ethyl ketone and diethyl ketone; and ethers such as diethyl ether and tetrahydrofuran. Preference is given to butyl acetate, toluene, dichloromethane, acetonitrile, chlorobenzene, nitrobenzene and N-dimethylformamide. The solvent can be used singly or in combination.
每 1摩尔羟基嘧啶化合物,溶剂可优选以 0. 01-10升,更优选以 0. 1-2升的 数量用于使用卤化剂的反应。 数量可根据反应混合物的均勾性和分散性变化。 The solvent may be preferably used in an amount of from 0.01 to 10 liters per 1 mole of the hydroxypyrimidine compound, more preferably in an amount of from 0.1 to 1 liter, for the reaction using a halogenating agent. The amount can vary depending on the homogeneity and dispersibility of the reaction mixture.
每 1摩尔羟基嘧啶化合物, 溶剂可优选以 0. 1-50升, 更优选以 0. 5-2升的 数量用于使用磺酰氯或磺酸酐的反应。数量可根据反应混合物的均匀性^分散性 变化。 The solvent may be preferably used in an amount of from 0.1 to 50 liters, more preferably from 0.5 to 2 liters per mole of the hydroxypyrimidine compound, using a sulfonyl chloride or a sulfonic acid anhydride. The amount may vary depending on the uniformity of the reaction mixture.
反应可通过使羟基嘧啶化合物和卤化剂在溶剂中在搅拌下在或不在惰性气 体气氛中反应进行。反应可优选在 0°C- 200°C,更优选 50°C-150°C的温度下进行。 关于环境压力没有特定限制。 The reaction can be carried out by reacting a hydroxypyrimidine compound and a halogenating agent in a solvent with or without stirring in an inert gas atmosphere. The reaction can be preferably carried out at a temperature of from 0 ° C to 200 ° C, more preferably from 50 ° C to 150 ° C. There are no specific restrictions on environmental stress.
反应可通过使羟基嘧啶化合物和磺酰基卤或磺酸酐在溶剂中在搅拌下在或 不在惰性气体气氛中反应进行。 反应可优选在 - 30°C-20(TC , 更优选 0-80Ό的温 度下进行。 关于环境压力没有特定限制。 The reaction can be carried out by reacting a hydroxypyrimidine compound and a sulfonyl halide or a sulfonic acid anhydride in a solvent with or without stirring in an inert gas atmosphere. The reaction can be preferably carried out at a temperature of from - 30 ° C to 20 (TC, more preferably from 0 to 80 Torr. There is no particular limitation on the environmental pressure.
反应生成的产物, 即 2-取代的嘧啶化合物, 例如氯嘧啶化合物或磺酰氧基 嘧啶化合物可根据常规方法, 例如蒸馏、 结晶、 重结晶和柱色谱法分离和纯化。 The product formed by the reaction, i.e., a 2-substituted pyrimidine compound such as a chloropyrimidine compound or a sulfonyloxypyrimidine compound, can be isolated and purified according to a conventional method such as distillation, crystallization, recrystallization, and column chromatography.
在步骤(3 ) 中制备的 2-取代的嘧啶化合物, 例如氯嘧啶化合物或磺酰氧基 嘧啶化合物与具有式 6的胺化合物反应: The 2-substituted pyrimidine compound prepared in the step (3), such as a chloropyrimidine compound or a sulfonyloxypyrimidine compound, is reacted with an amine compound having the formula 6:
式 6 Equation 6
其中!^和^与上述相同定义。 among them! ^ and ^ have the same definitions as above.
基团!^和 R2的实例包括氢原子、 垸基, 例如甲基、 乙基、 丙基、 丁基、 戊 基和已基; 垸基磺酰基, 例如甲磺酰基; 和芳基磺酰基, 例如苯磺酰基和对甲苯 磺酰基。 Group! Examples of ^ and R 2 include a hydrogen atom, a fluorenyl group such as a methyl group, an ethyl group, a propyl group, a butyl group, and a pentyl group. And a fluorenyl group; a mercaptosulfonyl group such as a methylsulfonyl group; and an arylsulfonyl group such as a benzenesulfonyl group and a p-toluenesulfonyl group.
每 1摩尔 2-取代的嘧啶化合物,胺化合物可优选以 0. 1-30摩尔,更优选 1-5 摩尔的数量使用。 The amine compound may preferably be used in an amount of from 0.1 to 30 moles, more preferably from 1 to 5 moles per 1 mole of the 2-substituted pyrimidine compound.
反应优选在碱存在下进行, 碱的实例是上述的那些碱。 The reaction is preferably carried out in the presence of a base, and examples of the base are those described above.
每 1摩尔 2-取代的羟基嘧啶化合物, 碱可优选以 0. 1-30摩尔, 更优选 1-5 摩尔的数量使用。 The base may be preferably used in an amount of from 0.1 to 30 moles, more preferably from 1 to 5 moles per 1 mole of the 2-substituted hydroxypyrimidine compound.
反应可以在溶剂存在下或不存在溶剂下进行,关于所使用的溶剂没有特定的 限制, 溶剂的实例包括水; 酮, 例如丙酮、 甲乙酮和二乙酮; 醚, 例如乙醚和四 氢呋喃; 酯, 例如乙酸乙酯、丙酸乙酯和乙酸丁酯; 腈, 例如乙腈和丙腈; 酰胺, 例如 N, N-二甲基甲酰胺和 N-甲基吡咯垸酮; 亚砜, 例如二甲基亚砜; 脲, 例如 N, N' -二甲基咪唑啉酮。 优选丙酮、 四氢呋喃、 乙酸乙酯、 乙酸丁酯、 乙腈、 N, N-二甲基甲酰胺和二甲基亚砜。尤其优选乙酸乙酯、 乙酸丁酯和乙腈。最优选乙 酸丁酯和乙腈。 溶剂可单独或组合地使用。 The reaction can be carried out in the presence or absence of a solvent, and the solvent to be used is not particularly limited, and examples of the solvent include water; ketones such as acetone, methyl ethyl ketone and diethyl ketone; ethers such as diethyl ether and tetrahydrofuran; Ethyl acetate, ethyl propionate and butyl acetate; nitriles such as acetonitrile and propionitrile; amides such as N, N-dimethylformamide and N-methylpyrrolidone; sulfoxides such as dimethyl sulfoxide Sulfone; urea, such as N, N'-dimethylimidazolidinone. Preference is given to acetone, tetrahydrofuran, ethyl acetate, butyl acetate, acetonitrile, N,N-dimethylformamide and dimethyl sulfoxide. Particularly preferred are ethyl acetate, butyl acetate and acetonitrile. Most preferred are butyl acetate and acetonitrile. The solvent can be used singly or in combination.
每 1摩尔 2-取代的嘧啶化合物,溶剂可优选以 0. 01-100升,更优选以 0. 5-5 升的数量使用。 数量可根据反应混合物的均匀性和分散性变化。 The solvent is preferably used in an amount of from 0.01 to 100 liters, more preferably from 0.5 to 5 liters per mole of the 2-substituted pyrimidine compound. The amount can vary depending on the uniformity and dispersibility of the reaction mixture.
反应可通过使 2-取代的嘧啶化合物和胺化合物在溶剂中在碱的存在下在搅 拌下在或不在惰性气体气氛中进行。 反应可优选在 -20°C-25(TC, 更优选 25°C - 150°C的温度下进行。 关于环境压力没有特定限制。 The reaction can be carried out by allowing the 2-substituted pyrimidine compound and the amine compound to be carried out in a solvent in the presence of a base with or without stirring in an inert gas atmosphere. The reaction can be preferably carried out at a temperature of from -20 ° C to 25 (TC, more preferably from 25 ° C to 150 ° C. There is no particular limitation on the environmental pressure.
在步骤 (3 ) 中在或不在相转移催化剂存在下反应, 在相转移催化剂存在下 反应时可在两个分幵的液体相中进行。 相转移催化剂的实例包括四甲基氯化铵、 四甲基溴化铵、 四甲基氟化铵、 四乙基氯化铵、 四乙基溴化铵、 四丙基溴化铵、 四丙基碘化铵、 四丁基氟化铵、 四丁基氯化铵、 四丁基溴化铵、 四丁基碘化铵、 四戊基溴化铵、 四已基溴化铵、 四庚基溴化铵、 四辛基溴化铵、 苄基二甲基十四 烷基氯化铵、 苯基三甲基氯化铵、 苯基三甲基碘化铵、 十六烷基三甲基氯化铵。 优选四丁基氯化铵、 四丁基溴化铵、 四丁基碘化铵、 苄基三乙基氯化铵、 十六垸 基三乙基氯化铰。最优选四丁基溴化铵、苄基三乙基氯化铵、十六垸基三甲基氯 化铵。 In step (3), the reaction is carried out in the presence or absence of a phase transfer catalyst, and the reaction in the presence of a phase transfer catalyst can be carried out in two branched liquid phases. Examples of the phase transfer catalyst include tetramethylammonium chloride, tetramethylammonium bromide, tetramethylammonium fluoride, tetraethylammonium chloride, tetraethylammonium bromide, tetrapropylammonium bromide, tetrapropylamine. Ammonium iodide, tetrabutylammonium fluoride, tetrabutylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium iodide, tetrapentylammonium bromide, tetrahexylammonium bromide, tetraheptyl Ammonium bromide, tetraoctyl ammonium bromide, benzyl dimethyltetradecyl ammonium chloride, phenyl trimethyl ammonium chloride, phenyl trimethyl ammonium iodide, cetyl trimethyl chloride Ammonium. Preferred are tetrabutylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium iodide, benzyltriethylammonium chloride, and hexadecanyltriethylphosphonium hinge. Most preferred are tetrabutylammonium bromide, benzyltriethylammonium chloride, and hexadecanyltrimethylammonium chloride.
每 1摩尔 2-取代的嘧啶化合物, 相转移催化剂可以 0. 01- 0. 5摩尔, 优选 0. 05-0. 2摩尔的数量使用。 0摩尔优选优选。 Each mole of 2-substituted pyrimidine compound, phase transfer catalyst may be 0. 01- 0. 5 moles, preferably 0. 05-0. The amount of 2 moles used.
反应生成的产物, 即式 4的 4_ (4-氟苯基) —6—异丙基 -5-氰基一 2_ (N 一甲基 _N—甲磺酰氨基)嘧啶可根据常规方法, 例如蒸馏、 结晶、 重结晶和柱 色谱法进行分离和纯化。 The product formed by the reaction, that is, 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine of the formula 4 can be obtained according to a conventional method, for example Separation and purification are carried out by distillation, crystallization, recrystallization and column chromatography.
在步骤(4) 中, 式 4的 4一 (4-氟苯基) 一6—异丙基 -5-氰基一 2— (N—甲 基一 N—甲磺酰氨基)嘧啶, 即步骤(3 )的反应产物与还原剂反应得到具有式 1 的 4一 (4-氟苯基) 一6—异丙基一 2_ (N—甲基一N—甲磺酰氨基) 嘧啶一 5— 甲醛。 In the step (4), 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine of the formula 4, ie, the step The reaction product of (3) is reacted with a reducing agent to obtain 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde having the formula 1. .
所述的还原剂可以是二异丁基氢化铝\ 红铝、 四氢铝锂等。若选用二异丁基 氢化铝, 则 4一 (4-氟苯基) 一 6—异丙基 -5-氰基一 2_ (N—甲基一 N—甲磺酰 氨基) 嘧啶 (式 4) 在有机溶剂中和惰性气体保护下滴加 5%〜65%二异丁基氢化 铝甲苯溶液,滴完后继续反应几小时, 反应结束后经分离和纯化得到取代嘧啶一 5—甲醛。 反应温度为- 20°C- 150°C, 优选- 10°C- 50°C。 The reducing agent may be diisobutylaluminum hydride, red aluminum, lithium tetrahydrogenate or the like. If diisobutylaluminum hydride is used, 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine (Formula 4) The 5%~65% diisobutylaluminum hydride toluene solution was added dropwise in an organic solvent under an inert gas atmosphere, and the reaction was continued for several hours after the completion of the dropwise addition. After the completion of the reaction, the substituted pyrimidine-5-formaldehyde was obtained by separation and purification. The reaction temperature is - 20 ° C to 150 ° C, preferably - 10 ° C to 50 ° C.
所述的有机溶剂可以是苯、 甲苯、 二甲苯、 二氯甲垸、 氯仿、 四氢呋喃、 二 氧六环及其它不与还原剂和反应原料反应的溶剂等。 The organic solvent may be benzene, toluene, xylene, dichloromethane, chloroform, tetrahydrofuran, dioxane or other solvent which does not react with a reducing agent and a reaction raw material.
4- (4-氟苯基) 一 6—异丙基 -5-氰基一 2_ (N—甲基一 N—甲磺酰氨基)嘧 啶与二异丁基氢化铝的摩尔比为 1. 0: 0. 5-10. 0, 优选 1. 0: 0. 8-4. 0。 The molar ratio of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine to diisobutylaluminum hydride is 1.0 0: 0-10. 0, Preferably 1. 0: 0. 8-4. 0.
本发明方法不需使用剧毒、昂贵原料,工艺成本低、反应简单、产物收率高、 宜于工业化生产。 The method of the invention does not need to use highly toxic, expensive raw materials, has low process cost, simple reaction, high product yield, and is suitable for industrial production.
本发明用如下非限制实施例进一步描述。 The invention is further described by the following non-limiting examples.
具体实施方式: detailed description:
[实施例 1] 4 - (4-氟苯基) - 6 异丙基 - 5-氰基- 3, 4-2 ( 1H) -二氢嘧啶 酮 (式 2) 的制备方法 [Example 1] Preparation method of 4-(4-fluorophenyl)-6 isopropyl 5-cyano-3,4-2(1H)-dihydropyrimidinone (Formula 2)
在 1000ml 配备有搅拌器、 温度计和回流冷凝器的玻璃烧瓶中加入 52. 2g (0. 47mol )异丁酰乙腈、 58. 3g (0. 47mol ) 4_氟苯甲醛、 49. 4g (0. 82mol )脲、 0. 53g (5. 3mmol ) 氯化亚酮 ( I )、 5. 3ml硫酸和 600ml 甲醇。 将烧瓶中的物质 在搅拌和加热下回流反应 22小时,冷至室温,有固体产生,过滤,用甲醇洗涤滤饼, 合并滤液和洗液,减压浓缩,得到 101. lg4- (4-氟苯基) -6-异丙基 -5-氰基 -3, 4-2 ( 1H) -二氢嘧啶酮具有下述特性的固体产物。 收率为 83% (基于异丁酰乙腈 的用量)。 5g (0. 47mol ) 4 - fluorobenzaldehyde, 49. 4g (0. 0g (0. 47mol) of isobutyryl acetonitrile, 58.3g (0. 47mol) of 4-fluorobenzaldehyde, 49. 4g (0. 82 mol) urea, 0.53 g (5.3 mmol) of chlorinated ketone (I), 5. 3 ml of sulfuric acid and 600 ml of methanol. The reaction flask were refluxed under stirring and heating 22 hours, cooled to room temperature, solid generated was filtered, the filter cake was washed with methanol, the filtrate and washings were combined, concentrated under reduced pressure, to give 101. l g 4- (4 -Fluorophenyl)-6-isopropyl-5-cyano-3,4-2(1H)-dihydropyrimidinone has a solid product of the following characteristics. Yield of 83% (based on isobutyryl acetonitrile) The amount).
m. p.: 174°C-178°C m. p.: 174°C-178°C
腹 (CH3CN, nra) :270 Belly (CH3CN, nra): 270
Ή-NMR (CDC13, δ (ppm)): 1.17-1.25 (6Η, d, J=6.8Hz), 3.0-3.2 (1H, m), 5.15 (lH,m) ,5.6 (lH,m) , 7.0-7.3 (2H, m), 7.2-7.4 (2H, m), 8.0 (1H, m)。 Ή-NMR (CDC13, δ (ppm)): 1.17-1.25 (6Η, d, J=6.8Hz), 3.0-3.2 (1H, m), 5.15 (lH,m), 5.6 (lH,m) , 7.0 -7.3 (2H, m), 7.2-7.4 (2H, m), 8.0 (1H, m).
[实施例 2] 4- (4-氟苯基) -6-异丙基 -5-氰基 -3, 4-2 (1H) -二氢嘧啶酮 (式 2) 的制备方法 [Example 2] 4-(4-Fluorophenyl)-6-isopropyl-5-cyano-3,4-2 (1H)-dihydropyrimidinone (Formula 2) Preparation Method
与实施例 1 的方法相同, 只是将甲醇的用量由 600ml 改为 200ml 得到 103.5g4- (4-氟苯基) -6-异丙基 -5-氰基- 3, 4-2 (1H) -二氢嘧啶酮具有例 1 特性的固体产物。 收率为 85% (基于异丁酰乙腈的用量)。 In the same manner as in Example 1, except that the amount of methanol was changed from 600 ml to 200 ml to obtain 103.5 g of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-3, 4-2 (1H)- The dihydropyrimidinone has the solid product of the characteristics of Example 1. The yield was 85% (based on the amount of isobutyrylacetonitrile).
[实施例 3] 4- (4-氟苯基) -6-异丙基 -5-氰基- 3, 4-2 (1H) -二氢嘧啶酮 (式 2) 的制备方法 [Example 3] 4-(4-Fluorophenyl)-6-isopropyl-5-cyano-3,4-2(1H)-dihydropyrimidinone (Formula 2)
与实施例 1的方法相同, 只是将脲的用量由 49.4 g (0.82raol)改为 56.63 g (0.94mol)得到 106.3g4- (4-氟苯基) -6-异丙基 -5-氰基- 3, 4-2 (1H) -二氢 嘧啶酮具有例 1特性的固体产物。 收率为 87.2% (基于异丁酰乙腈的用量)。 In the same manner as in Example 1, except that the amount of urea was changed from 49.4 g (0.82 raol) to 56.63 g (0.94 mol) to obtain 106.3 g of 4-(4-fluorophenyl)-6-isopropyl-5-cyano group. - 3, 4-2 (1H)-Dihydropyrimidinone has the solid product of the characteristics of Example 1. The yield was 87.2% (based on the amount of isobutyrylacetonitrile).
[实施例 4] 4- (4-氟苯基) -6-异丙基 -5-氰基 _3, 4-2 (1H) -二氢嘧啶酮 (式 2) 的制备方法 [Example 4] 4-(4-Fluorophenyl)-6-isopropyl-5-cyano- 3,4-2 (1H)-dihydropyrimidinone (Formula 2)
与实施例 1的方法相同, 只是用 14.33g (53mmol)氯化铁 (III) .六水合物 代替 530mg (5.3動1) 氯化酮 ( I ), 得到 79.2g4- (4-氟苯基) -6-异丙基 -5- 氰基- 3, 4-2 (1H) -二氢嘧啶酮具有例 1特性的固体产物。 收率为 65% (基于异 丁酰乙腈的用量)。 In the same manner as in Example 1, except that 14.33 g (53 mmol) of iron(III) chloride and hexahydrate were used instead of 530 mg (5.3 of 1) of chlorinated ketone (I), 79.2 g of 4-(4-fluorophenyl) was obtained. -6-Isopropyl-5-cyano-3,4-2(1H)-dihydropyrimidinone has the solid product of the characteristics of Example 1. The yield was 65% (based on the amount of isobutyrylacetonitrile).
[实施例 5] 4- (4-氟苯基) -2-羟基 -6-异丙基 -5-氰基嘧啶 (式 3) 的制备 方法 [Example 5] Preparation method of 4-(4-fluorophenyl)-2-hydroxy-6-isopropyl-5-cyanopyrimidine (Formula 3)
在 250ml 配备搅拌器和温度计的玻璃烧瓶中加入 120ml (1.57mol) 硝酸 (60-61%, sp.gr·: 1.38)。 在 10Ό以下向硝酸中缓慢加入以实施例 1中的相 同方法制备的 33g (0.127mol) 4- (4-氟苯基) -6-异丙基 -5-氰基- 3, 4-2 (1H) -二氢嘧啶酮, 混合物在室温下反应 50分钟。在反应完成后, 通过将混合物加入 1500ml 饱和碳酸氢钠水溶液中和反应混合物, 产生白色固体, 过滤, 水洗, 烘 干。 得到 29. 26g具有下述特性的 4- (4-氟苯基) -2-羟基 -6-异丙基 -5-氰基嘧 啶白色固体产物。 收率为 89% (基于 4- (4-氟苯基) -6-异丙基 -5-氰基 -3, 4-2 ( 1H) -二氢嘧啶酮的数量)。 Into a 250 ml glass flask equipped with a stirrer and a thermometer, 120 ml (1.57 mol) of nitric acid (60-61%, sp. gr.: 1.38) was added. 33 g (0.127 mol) of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-3, 4-2 (in the same manner as in Example 1) was slowly added to nitric acid below 10 Torr. 1H)-Dihydropyrimidinone, the mixture was reacted at room temperature for 50 minutes. After the reaction is completed, the mixture is neutralized by adding 1500 ml of a saturated aqueous solution of sodium hydrogencarbonate to give a white solid, which is filtered, washed with water and dried. Dry. 29.26 g of 4-(4-fluorophenyl)-2-hydroxy-6-isopropyl-5-cyanopyrimidine as a white solid product. The yield was 89% (based on the amount of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-3,4-2(1H)-dihydropyrimidinone).
m. p. : 199. 1°C (分解) m. p. : 199. 1 ° C (decomposition)
υν λ丽 (CH3CN, nm): 244. 8, 317. 6 Υν λ丽 (CH3CN, nm): 244. 8, 317. 6
[实施例 6] 4- (4-氟苯基) -2-羟基 -6-异丙基 -5-氰基嘧啶的制备方法 在 250ml 配备搅拌器和温度计的玻璃烧瓶中加入 64. 8g ( 882画 ol ) 硝酸 (60-61%, sp. gr. : 1. 38)。在室温下向硝酸中缓慢加入以实施例 1中的相同方 法制备的 30. 6g ( 118腿 ol ) 4- (4-氟苯基) _6 -异丙基- 5-氰基- 3, 4-2 ( 1H) - 二氢嘧啶酮, 混合物在室温下反应 30分钟。 在反应完成后, 将反应混合物倾倒 入 162ml水中, 含水混合物通过加入 78. lg含水氢氧化钠溶液 (45wt%) 中和, 含水混合物以沉淀结晶。通过过滤收集结晶产物,干燥得到 28. 3g4- (4-氟苯基) -2 -轻基 -6-异丙基 -5-氰基嘧啶白色结晶产物。 收率为 93% (基于 4- (4-氟苯基) -6 -异丙基 -5-氰基- 3, 4-2 ( 1H) -二氢嘧啶酮的数量)。 [8] </ br> </ br> </ br> </ br> </ br> </ br> </ br> </ br> </ br> Draw ol) nitric acid (60-61%, sp. gr.: 1. 38). 6克(118腿ol) 4-(4-fluorophenyl)-6-isopropyl-5-cyano-3, 4-, prepared by the same method as in Example 1 was slowly added to the nitric acid at room temperature. 2 (1H)-dihydropyrimidinone, the mixture was reacted at room temperature for 30 minutes. After completion of the reaction, the reaction mixture was poured into 162 ml of water, and the aqueous mixture was neutralized by adding 78. lg of an aqueous sodium hydroxide solution (45 wt%), and the aqueous mixture was crystallized by precipitation. The crystalline product was collected by filtration and dried to give 28.3 g of 4-(4- fluorophenyl) - 2 - s yl -6 - isopropyl - 5-cyanopyrimidine as white crystals. The yield was 93% (based on the amount of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-3,4-2(1H)-dihydropyrimidinone).
[实施例 7] 4- (4-氟苯基) -2-羟基- 6-异丙基 -5-氰基嘧啶的制备方法 在配备搅拌器和温度计的 1L 玻璃烧瓶中加入 161. 6g ( 1. 54mol ) 硝酸 (60 - 61%, sp. gr. : 1. 38)。将浓硝酸冷却到 10°C,向硝酸中加入 1. 2g( 17. 4励 1 ) 亚硝酸钠, 然后缓慢加入 44. 3g ( 171mmol ) 以实施例 1中的相同方法制备的 4 - (4-氟苯基) - 6-异丙基 -5-氰基 -3, 4 2 ( 1H) -二氢嘧啶酮。 混合物在 10°C - 15 °C的温度下反应 2小时。在反应完成后, 将 500ml水倒入反应混合物中, 通过加 入 137g含水氢氧化钠水溶液(45wt%)中和含水混合物以沉淀结晶。通过过滤收 集结晶产物, 干燥得到 40. 6g4- (4-氟苯基) -2-羟基- 6-异丙基 -5-氰基嘧啶无 色结晶产物。 收率为 92% (基于 4- (4-氟苯基) - 6-异丙基 - 5_氰基- 3, 4-2 ( 1H) -二氢嘧啶酮的数量)。 6克 (1) In a 1 L glass flask equipped with a stirrer and a thermometer, 161.6 g (1) . 54mol ) Nitric acid (60 - 61%, sp. gr.: 1. 38). The concentrated nitric acid was cooled to 10 ° C, and 1. 2 g ( 17. 4 Torr 1 ) of sodium nitrite was added to the nitric acid, followed by the slow addition of 44.3 g ( 171 mmol ) of the 4 - (4) prepared in the same manner as in Example 1. -fluorophenyl)-6-isopropyl-5-cyano-3, 4 2 (1H)-dihydropyrimidinone. The mixture was reacted at a temperature of from 10 ° C to 15 ° C for 2 hours. After the completion of the reaction, 500 ml of water was poured into the reaction mixture, and the aqueous mixture was precipitated by adding 137 g of an aqueous aqueous sodium hydroxide solution (45 wt%) to precipitate crystals. The crystalline product was collected by filtration and dried to give 40. 6 g of 4-(4-fluorophenyl)-2-hydroxy-6-isopropyl-5-cyanopyrimidine as a colorless crystal. The yield was 92% (based on the amount of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-3,4-2(1H)-dihydropyrimidinone).
[实施例 8] 4- (4-氟苯基) -6-异丙基 -5-氰基- 2- (N-甲基- N-甲磺酰氨基) 嘧啶 (式 4) 的制备方法 [Example 8] 4-(4-Fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine (Formula 4)
在 500ml配备搅拌器、温度计和回流冷凝器的玻璃烧瓶中加入 28g( 108mmol ) 4- (4-氟苯基) -2-羟基 -6-异丙基 -5-氰基嘧啶、 17g ( 123mmol ) 粉状碳酸钾和 16.0ml乙酸丁酯。在搅拌下向混合物中缓慢加入 22g ( 115mm0l )对甲苯磺酰基氯, 反应在 50°C下进行 3小时。 随后将反应混合物冷却到室温, 向冷却的反应混合 物中加入 12. lg (llOmmol) N-甲基甲磺酰胺和 18g (130mmol) 碳酸钾。 在回流 下混合物加热到 110°C-125°C2小时以迸行反应。 在反应完成后, 将混合物冷却 到室温。 向冷却的混合物中加入 100ml水, 分离出有机液体部分。有机液体部分 用饱和氯化钠水溶液洗涤, 用无水硫酸镁干燥, 并减压浓缩。残余物由丙酮结晶 得到 32.6g具有下述特性的 4- (4 -氟苯基) -6-异丙基 -5-氰基- 2- (N-甲基- N- 甲磺酰基氨基) 嘧啶浅黄色结晶产物。 收率为 86% (基于 4- (4-氟苯基) -2 -径 基 -6-异丙基 -5-氰基嘧啶的数量)。 In a 500 ml glass flask equipped with a stirrer, a thermometer and a reflux condenser, 28 g (108 mmol) of 4-(4-fluorophenyl)-2-hydroxy-6-isopropyl-5-cyanopyrimidine, 17 g (123 mmol) were added. Powdered potassium carbonate and 16.0 ml of butyl acetate. 22 g (115 mm 0 l) of p-toluenesulfonyl chloride was slowly added to the mixture with stirring. The reaction was carried out at 50 ° C for 3 hours. The reaction mixture was then cooled to room temperature and 12. lg (10 mmol) of N-methylmethanesulfonamide and 18 g (130 mmol) of potassium carbonate were added to the cooled reaction mixture. The mixture was heated to 110 ° C - 125 ° C for 2 hours under reflux to carry out the reaction. After the reaction was completed, the mixture was cooled to room temperature. To the cooled mixture was added 100 ml of water, and the organic liquid fraction was separated. The organic liquid portion was washed with a saturated aqueous The residue was crystallized from acetone to give 32.6 g of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine. Light yellow crystalline product. The yield was 86% (based on the amount of 4-(4-fluorophenyl)-2-isoyl-6-isopropyl-5-cyanopyrimidine).
m. p.: 208°C-212°C m. p.: 208°C-212°C
UVXmax (CH3CN, nm) :252.8 UVXmax (CH3CN, nm): 252.8
lH-NMR (CDC13, δ (ppm)): 1.37—1.40 (6H, d), 3.5— 3.6 (3H, m), 3.6-3.7 (3H, m), 3.6-3.7 (1H, ra), 7.2-7.3 (2H, m), 8.0-8.2 (2H, m) . lH-NMR (CDC13, δ (ppm)) : 1.37-1.40 (6H, d), 3.5-3.6 (3H, m), 3.6-3.7 (3H, m), 3.6-3.7 (1H, ra), 7.2- 7.3 (2H, m), 8.0-8.2 (2H, m).
[实施例 9] 4- (4-氟苯基) -6-异丙基 -5-氰基- 2- (N-甲基- N-甲磺酰基氨 基) 嘧啶的制备方法 [Example 9] Preparation method of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine
在配备搅拌器、 温度计和回流冷凝器的 500ml 玻璃烧瓶中加入 22.2g (86mraol) 4- (4-氟苯基) -2-羟基- 6-异丙基 -5 -氰基嘧啶、 10.4g (94.5mmol) 叔戊醇钠和 165ml乙腈, 得到的混合物在 0°C- 10°C下搅拌 30分钟。 向混合物缓 慢加入 18.0g (94.5mmol)对甲苯磺酰氯, 反应在室温下进行 5小时。 随后将冷 却到 0- 10°C的温度, 向冷却的反应混合物中加入 14. lg (129腿 ol) N-甲基甲磺 酰胺和 13.25g (120.5mmol) 叔戊醇钠。 混合物保持在 0°C_1(TC1小时, 随后在 回流下在 75°C- 82°C下加热 3小时以进行反应。 在反应完成后, 将混合物冷却到 室温。 向冷却的混合物中加入 180ml水。将含水混合物冷却到 O'C- 10°C, 搅拌 1 小时, 沉淀结晶产物。 过滤收集结晶产物, 干燥得到 18.9g4- (4-氟苯基) -6 - 异丙基 -5-甲氧基羰基 -2- (N-甲基 -N-甲磺酰基氨基) 嘧啶浅黄色结晶产物。 收 率为 63% (基于 4- (4-氟苯基) -2-羟基- 6-异丙基 -5-氰基嘧啶的数量)。 In a 500 ml glass flask equipped with a stirrer, a thermometer and a reflux condenser, 22.2 g (86 mraol) of 4-(4-fluorophenyl)-2-hydroxy-6-isopropyl-5-cyanopyrimidine, 10.4 g ( 94.5 mmol) sodium t-pentoxide and 165 ml acetonitrile, and the resulting mixture was stirred at 0 ° C - 10 ° C for 30 minutes. To the mixture was slowly added 18.0 g (94.5 mmol) of p-toluenesulfonyl chloride, and the reaction was carried out at room temperature for 5 hours. Subsequently, it was cooled to a temperature of 0 - 10 ° C, and 14. lg (129 leg ol) of N-methylmethanesulfonamide and 13.25 g (120.5 mmol) of sodium t-pentoxide were added to the cooled reaction mixture. The mixture was kept at 0 ° C 1 (TC 1 hour, followed by heating at 75 ° C - 82 ° C for 3 hours under reflux to carry out the reaction. After the reaction was completed, the mixture was cooled to room temperature. To the cooled mixture was added 180 ml of water. The aqueous mixture was cooled to O'C - 10 ° C and stirred for 1 hour to precipitate a crystalline product. The crystallized product was collected by filtration and dried to give 18.9 g of 4-(4-fluorophenyl)-6-isopropyl-5-methoxy. a light yellow crystalline product of carbonyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine. Yield 63% (based on 4-(4-fluorophenyl)-2-hydroxy-6-isopropyl- The number of 5-cyanopyrimidines).
[实施例 10] 4- (4-氟苯基) -6-异丙基 -5-氰基 -2- (N-甲基- N-甲磺酰氨基) 嘧啶 (式 4) 的制备方法 [Example 10] Preparation method of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine (Formula 4)
在 500ml配备搅拌器、温度计和回流冷凝器的玻璃烧瓶中加入 28g(108mmol) 4- (4-氟苯基) -2-羟基- 6-异丙基 -5-氰基嘧啶、 17g (123睡 ol) 粉状碳酸钾和 120ml乙腈。 在搅拌下向混合物中缓慢加入 22g ( 115mmol )对甲苯磺酰基氯, 反 应在 50°C下进行 3小时。 随后将反应混合物冷却到室温, 向冷却的反应混合物 中加入 12. lg ( l lOfflmol ) N-甲基甲磺酰胺和 18g ( 130ramol ) 碳酸钾。 在加热下 混合物回流反应 3小时。在反应完成后, 将混合物冷却到室温。 向冷却的混合物 中加入 100ml水和 300ml乙酸乙酯, 分离出有机液体部分。有机液体部分用饱和 氯化钠水溶液洗涤, 用无水硫酸镁干燥, 并减压浓缩。 残余物由丙酮结晶得到 31. 8g具有上述特性的 4- (4-氟苯基) -6-异丙基 -5-氰基- 2- (N-甲基- N-甲磺酰 基氨基)嘧啶浅黄色结晶产物。 收率为 83. 9% (基于 4- (4-氟苯基) - 2-羟基 -6- 异丙基 -5-氰基嘧啶的用量)。 In a 500 ml glass flask equipped with a stirrer, a thermometer and a reflux condenser, 28 g (108 mmol) of 4-(4-fluorophenyl)-2-hydroxy-6-isopropyl-5-cyanopyrimidine, 17 g (123 slept) were added. Ol) powdered potassium carbonate and 120 ml of acetonitrile. 22 g (115 mmol) of p-toluenesulfonyl chloride was slowly added to the mixture under stirring, and the reaction was carried out at 50 ° C for 3 hours. The reaction mixture was then cooled to room temperature, and 12. lg (l l Offlmol) of N-methylmethanesulfonamide and 18 g (130 ramol) of potassium carbonate were added to the cooled reaction mixture. The mixture was refluxed for 3 hours while heating. After the reaction was completed, the mixture was cooled to room temperature. To the cooled mixture was added 100 ml of water and 300 ml of ethyl acetate, and the organic liquid fraction was separated. The organic liquid portion was washed with a saturated aqueous The residue was crystallized from acetone to give 31.8 g of 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine. Light yellow crystalline product. The yield was 83.9% (based on the amount of 4-(4-fluorophenyl)-2-hydroxy-6-isopropyl-5-cyanopyrimidine).
[实施例 11] 4一 (4-氟苯基) 一6—异丙基 _2— (N—甲基一N—甲磺酰氨基) 嘧啶一 5—甲醛 (式 1 ) 的制备方法 [Example 11] Preparation method of 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde (Formula 1)
在 250ml 配备搅拌器、 温度计和回流冷凝器的玻璃烧瓶中加入 2. 00g Add 2. 00g to a 250ml glass flask equipped with a stirrer, thermometer and reflux condenser
(5. 73mmol ) 4- (4-氟苯基) -6-异丙基 -5-氰基- 2- (N-甲基- N-甲磺酰基氨基) 嘧啶和 20ml氯仿,搅拌下慢慢加入 9 ml (10. 5ramol ) 20%二异丁基氢化铝甲苯溶 液,5°〇-10°〇反应6小时,加入2 1^乙醇5再加入201^ 冰水。 分出有机层, 水层用 氯仿提取 2 次, 合并有机层, 水洗至中性, 浓缩, 得淡黄色固体 1.61 克,收率 80%,mp:175°C-177°C。 (5. 73 mmol) 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine and 20 ml of chloroform, slowly stirring Add 9 ml (10. 5ramol) of 20% diisobutylaluminum hydride in toluene solution, react at 5 ° 〇 -10 ° for 6 hours, add 2 1 ^ ethanol 5 and then add 201 ^ ice water. The organic layer was separated, and the aqueous layer was extracted twice with chloroform. The organic layer was combined, washed with water to neutral, and concentrated to give a pale yellow solid, 1.61 g, yield 80%, mp: 175 ° C - 177 ° C.
[实施例 12] 4— (4-氟苯基) 一 6—异丙基一 2— (N—甲基一N—甲磺酰氨基) 嘧啶一 5—甲醛 (式 1 ) 的制备方法 [Example 12] 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde (Formula 1)
在 1000ml 配备搅拌器、 温度计和回流冷凝器的玻璃烧瓶中加入 8. 00g Add 8. 00g to a 1000ml glass flask equipped with a stirrer, thermometer and reflux condenser
(22. 92mmol ) 4- (4-氟苯基) -6-异丙基 -5-氰基 -2- (N-甲基- N-甲磺酰基氨基) 嘧啶和 60ml氯仿,搅拌下慢慢加入 40 ml (46. 7mmol ) 20%二异丁基氢化铝甲苯溶 液, 5°C-10°C反应 5小时,加入 8 ml乙醇,再加入 100ml冰水。 分出有机层, 水层 用氯仿提取 2次, 合并有机层, 水洗至中性, 浓缩, 得淡黄色固体 7.1 克,收率 87%,mp:175°C-177°C。 (22.92 mmol) 4-(4-fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino)pyrimidine and 60 ml of chloroform, slowly stirred 40 ml (46. 7 mmol) of 20% diisobutylaluminum hydride in toluene was added, and the reaction was carried out at 5 ° C to 10 ° C for 5 hours, 8 ml of ethanol was added, and 100 ml of ice water was added thereto. The organic layer was separated, and the aqueous layer was extracted twice with chloroform. The organic layer was combined, washed with water to neutral, and concentrated to give a pale yellow solid 7.1 g, yield 87%, mp: 175 ° C - 177 ° C.
[实施例 13] 4- (4-氟苯基) 一 6—异丙基一2— (N—甲基一N—甲磺酰氨基) 嘧啶一 5—甲醛 (式 1 ) 的制备方法 [Example 13] 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde (Formula 1)
在 250ral 配备搅拌器、 温度计和回流冷凝器的玻璃烧瓶中加入 2. 00g Add 2. 00g to a 250ral glass flask equipped with a stirrer, thermometer and reflux condenser
(5. 73mmol ) 4- (4-氟苯基) -6-异丙基 -5-氰基- 2- (N-甲基 -N-甲磺酰基氨基) 嘧啶和 40ml甲苯,搅拌下慢慢加入 8 ml40%红铝甲苯溶液,25°C-30°C反应 5小时, 加入 2 ml乙醇,再加入 20ml冰水。 分出有机层, 水层用甲苯提取 2次, 合并有 机层, 水洗至中性, 浓缩, 得淡黄色固体 1.59克,收率 79%,mp:I75°C-177°C。 (5. 73 mmol) 4-(4-Fluorophenyl)-6-isopropyl-5-cyano-2-(N-methyl-N-methylsulfonylamino) Pyrimidine and 40 ml of toluene were slowly added with 8 ml of 40% red aluminum toluene solution under stirring, and reacted at 25 ° C to 30 ° C for 5 hours, 2 ml of ethanol was added, and 20 ml of ice water was added thereto. The organic layer was separated, and the aqueous layer was extracted twice with toluene. The organic layer was combined, washed with water to neutral, and concentrated to give a pale yellow solid 1.59 g, yield 79%, mp: I75 ° C - 177 ° C.
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710041850.6 | 2007-06-11 | ||
| CN200710041850A CN101323597B (en) | 2007-06-11 | 2007-06-11 | Preparation of 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyl amido) pyrimidine-5-formaldehyde |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008151510A1 true WO2008151510A1 (en) | 2008-12-18 |
Family
ID=40129223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2008/001083 Ceased WO2008151510A1 (en) | 2007-06-11 | 2008-06-02 | Preparation of 4-(fluorophenyl)-6-isopropyl-2-(n-methyl-n-methylsulfonylamino)- 5-formyl-pyrimidine |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101323597B (en) |
| WO (1) | WO2008151510A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012013325A1 (en) | 2010-07-26 | 2012-02-02 | Lek Pharmaceuticals D.D. | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof |
| WO2012172564A1 (en) * | 2011-05-25 | 2012-12-20 | Dr. Reddy's Laboratories Limited | Process for preparation of rosuvastatin calcium |
| WO2016116589A1 (en) * | 2015-01-23 | 2016-07-28 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Improved process for preparing statin precursor |
| WO2016151104A1 (en) * | 2015-03-26 | 2016-09-29 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Improved process for preparing a statin precursor |
| CN115677598A (en) * | 2022-11-11 | 2023-02-03 | 南通常佑药业科技有限公司 | Preparation method for synthesizing pyrimidinedione compound |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103113308B (en) * | 2013-01-25 | 2014-11-19 | 浙江大学 | A method for preparing dihydropyrimidinone derivatives |
| CN104059024B (en) * | 2014-06-16 | 2016-04-06 | 浙江大学 | The preparation method of Rosuvastatin intermediate and midbody compound |
| CN104774183B (en) * | 2015-04-24 | 2017-10-13 | 合肥新诺华生物科技有限公司 | A kind of auspicious relax of formoxyl cuts down the preparation method of spit of fland calcium intermediate |
| CN106632071B (en) * | 2016-09-29 | 2021-07-09 | 陕西师范大学 | A method for the efficient catalytic preparation of 3,4-dihydropyrimidin-2-one derivatives by promoting dichlorotitanocene with ethanol |
| CN111138369A (en) * | 2019-12-17 | 2020-05-12 | 上海雅本化学有限公司 | Preparation method of rosuvastatin intermediate |
| CN112174898B (en) * | 2020-11-06 | 2021-05-04 | 浙江宏元药业股份有限公司 | Novel method for preparing hydroxypyrimidine by continuously oxidizing dihydropyrimidinone |
| CN113135859B (en) * | 2021-04-26 | 2022-08-26 | 安徽省庆云医药股份有限公司 | Green synthesis method of rosuvastatin calcium intermediate |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003097614A2 (en) * | 2002-05-21 | 2003-11-27 | Ranbaxy Laboratories Limited | Process for the preparation of rosuvastatin |
| CN1527821A (en) * | 2001-07-13 | 2004-09-08 | Process for preparing aminopyrimidine compounds | |
| WO2007007119A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Uk Limited | Processes for the manufacture of rosuvastatin and intermediates |
-
2007
- 2007-06-11 CN CN200710041850A patent/CN101323597B/en active Active
-
2008
- 2008-06-02 WO PCT/CN2008/001083 patent/WO2008151510A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1527821A (en) * | 2001-07-13 | 2004-09-08 | Process for preparing aminopyrimidine compounds | |
| WO2003097614A2 (en) * | 2002-05-21 | 2003-11-27 | Ranbaxy Laboratories Limited | Process for the preparation of rosuvastatin |
| WO2007007119A1 (en) * | 2005-07-08 | 2007-01-18 | Astrazeneca Uk Limited | Processes for the manufacture of rosuvastatin and intermediates |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012013325A1 (en) | 2010-07-26 | 2012-02-02 | Lek Pharmaceuticals D.D. | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof |
| EP2423195A1 (en) | 2010-07-26 | 2012-02-29 | LEK Pharmaceuticals d.d. | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof |
| US9085538B2 (en) | 2010-07-26 | 2015-07-21 | Lek Pharmaceuticals D.D. | Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof |
| WO2012172564A1 (en) * | 2011-05-25 | 2012-12-20 | Dr. Reddy's Laboratories Limited | Process for preparation of rosuvastatin calcium |
| WO2016116589A1 (en) * | 2015-01-23 | 2016-07-28 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Improved process for preparing statin precursor |
| CN107428703A (en) * | 2015-01-23 | 2017-12-01 | 中化帝斯曼制药有限公司荷兰公司 | For preparing the improved method of statin precursor |
| US10246423B2 (en) * | 2015-01-23 | 2019-04-02 | Centrient Pharmaceuticals Netherlands B.V. | Process for preparing statin precursor |
| CN107428703B (en) * | 2015-01-23 | 2021-01-12 | 灿盛制药有限公司荷兰公司 | Improved process for the preparation of statin precursors |
| EP3247703B1 (en) * | 2015-01-23 | 2024-10-16 | Centrient Pharmaceuticals Netherlands B.V. | Improved process for preparing statin precursor |
| WO2016151104A1 (en) * | 2015-03-26 | 2016-09-29 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Improved process for preparing a statin precursor |
| CN107428702A (en) * | 2015-03-26 | 2017-12-01 | 中化帝斯曼制药有限公司荷兰公司 | Improved method for preparing statin precursors |
| CN115677598A (en) * | 2022-11-11 | 2023-02-03 | 南通常佑药业科技有限公司 | Preparation method for synthesizing pyrimidinedione compound |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101323597A (en) | 2008-12-17 |
| CN101323597B (en) | 2012-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008151510A1 (en) | Preparation of 4-(fluorophenyl)-6-isopropyl-2-(n-methyl-n-methylsulfonylamino)- 5-formyl-pyrimidine | |
| KR100888408B1 (en) | Process for preparing aminopyrimidine compound | |
| CA2935594C (en) | 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one and processes for their preparation | |
| AU2002318041A1 (en) | Preparation of aminopyrimidine compounds | |
| WO2020097971A1 (en) | Catalyst system and method for preparing azoxystrobin or intermediates thereof by using catalyst system | |
| US4705791A (en) | Substituted pyrimidin-2-ones and the salts thereof | |
| CN104059024B (en) | The preparation method of Rosuvastatin intermediate and midbody compound | |
| JP2003506312A (en) | Meta-nitrophenol derivative and method for producing the same | |
| RU2301801C2 (en) | Method for preparing sulfonulaminopyrimidine compounds (variants), intermediate substances and methods for their preparing | |
| JP2000063377A (en) | Method for producing substituted pyridine | |
| JP2003520762A (en) | Preparation of thiobarbituric acid derivatives | |
| TWI245759B (en) | Preparation of aminopyrimidine compounds | |
| HK1064384B (en) | Preparation of aminopyrimidine compounds | |
| JP2660330B2 (en) | Thiophene derivative and method for producing the same | |
| JP2003506311A (en) | Method for producing toluenesulfinate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08772927 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08772927 Country of ref document: EP Kind code of ref document: A1 |